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Chapter I 
MODELS OF GASTRIC CORPUS NEOPLASIA AND INFLAMMATION 
 
Adapted From: Petersen, C. P., Mills, J.C. and Goldenring J.R.  Murine models of gastric 
fundic neoplasia and inflammation. 
 
 Gastric adenocarcinoma leads in worldwide cancer-related deaths.  Poor clinical 
outcomes result from the lack of early clinical indicators.  Insights into the progression of pre-
neoplastic processes that promote gastric cancer are therefore a necessity.  Murine models 
are currently used to understand the molecular mechanisms driving metaplasia in the stomach 
towards cancer.  At the outset however, it should be noted that no mouse models have 
produced true tumor masses in the body of the stomach that lead to local or distal metastasis.  
Therefore, the general utility of mouse models lies in the evolution of precancerous lesions and 
the analysis of mechanisms that are responsible for the induction and presence of metaplasia.  
The following discussion will examine models of gastric neoplasia in mice and the insights 
provided into the origin and progression of human disease. 
 
1. Definition of hyperplastic, metaplastic and pre-neoplastic lineages in mouse stomach 
models: 
 There is considerable variability in the nomenclature used to assign pathology changes 
observed in the gastric mucosa.  This has resulted in poor understanding of the cellular 
processes that lead to adenocarcinoma. Therefore in effort to standardize the nomenclature, 
we impart specific biomarkers that positively identifies key epithelial changes that occur during 
the progression of metaplasia. This adoption of terminology that specifies certain pathology 
features is necessary to then accurately classify cellular changes at key stages.  Described 
below are terms used to describe different observed states in the metaplastic process.  Figure 
	   2	  
1 illustrates these specific changes in the gastric mucosa during the development and 
progression of metaplasia. Furthermore, Table 1 provides specific biomarkers that differentiate 
the different stages of metaplasia. 
 
Oxyntic atrophy.   
 The loss of parietal cells, also known as oxyntic atrophy, is considered the sine qua non 
for the development of metaplasia in the human stomach (Eidt et al., 1996). In humans and 
mice, chronic Helicobacter infection leads to loss of parietal cells in the corpus of the stomach 
(Fox et al., 1996; Fox et al., 2003; Wang et al., 2000b; Wang et al., 1998).  Oxyntic atrophy 
can be diagnosed on hematoxylin and eosin staining based on the loss of eosinophilic parietal 
cells as well as hematoxylin-positive chief cells (Figure 1 Aii).  More definitive analysis of these 
lineages can be made using specific markers for these lineages including H/K-ATPase 
antibodies for parietal cells and antibodies against either intrinsic factor or the transcription 
factor Mist1 for chief cells (Figure 1 Bii). 
 
Foveolar hyperplasia.   
 Foveolar hyperplasia represents an expansion of the surface mucous cell compartment.  
It is usually associated with an increase in proliferation in the normal neck progenitor cells 
(Nomura et al., 2005b) (Figure 1 ii).  Increases in foveolar hyperplasia are associated with 
elevations in gastrin (Poynter et al., 1986), or TGF-alpha (as observed in human Menetrier’s 
disease) (Dempsey et al., 1992a).  Oxyntic atrophy and resulting loss of acid secretion is 
usually associated with varying levels of foveolar hyperplasia commensurate with the level of 
hypochlorhydria. 
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Mucus neck cell hyperplasia.  
  Mucous neck cell hyperplasia or mucous metaplasia connotes and expansion of the 
mucous neck cells in the middle region of corpus glands in the stomach (Figure 1 ii).  Mucous 
metaplasia has been reported in a number of settings with alterations of ion channels or 
endocrine cell influences (Lee et al., 2000). The expansion of mucous neck cells is not 
associated with proliferation within the mucous neck cell population, but rather appears to 
reflect either an increased production of mucous neck cells from progenitors or a slowing of 
differentiation of mucous neck cells into chief cells.  Proliferative (Ki67 positive) GSII–lectin 
positive cells is indicative of mucus neck cell hyperplasia (Figure 1Bii).  
 
Spasmolytic Polypeptide-expressing Metaplasia (SPEM).   
 Loss of parietal cells in the stomach leads to transdifferentiation of chief cells into SPEM 
(Figure 1iii).  This lineage was originally characterized by its expression of spasmolytic 
polypeptide, now designated TFF2 (Schmidt et al., 1999b). This lineage can often be identified 
by pink staining in Diastase-resistant-PAS staining, compared with the purple staining in 
surface mucous cells (Goldenring and Nomura, 2006). This lineage appears to overlap with 
previously-described pathologies including pseudopyloric metaplasia (Hattori et al., 1982) and 
Ulcer-associated lineages (UACL) (Wright et al., 1990). Several markers of SPEM have been 
characterized that are not present in the normal stomach, including HE-4 (WFDC2) (Nozaki et 
al., 2008b) and CD44variant (Wada et al., 2013). Some studies have noted the identification of 
proliferative cells expressing both gastric intrinsic factor and TFF2 along with Ki-67 as 
reflective of SPEM induction (Weis et al., 2013b) (Figure 1Biii). Nevertheless, it is clear in a 
number of models that morphological apparent SPEM lineages can often show varying levels 
of intestinalizing transcripts including MAL2, CFTR and Muc4 (Weis et al., 2014; Weis et al., 
2013b). This intestinalized SPEM is morphologically identical to other SPEM lineages and can 
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only be recognized by immunostaining with specific intestinal markers or Ki67 positive SPEM 
cells (Figure 1 iv) (Weis et al., 2013b).  
 
Intestinal Metaplasia.   
 While both SPEM and intestinal metaplasia are present in the stomachs of humans with 
atrophic gastritis secondary to H. pylori infection (Lennerz et al., 2010), few instances of 
documented intestinal metaplasia exist in mouse models.  In human stomach, Alcian blue 
staining of intestinal type goblet cells is often used to define intestinal metaplasia.  However, in 
mice, deep antral mucous cells are strongly Alcian blue positive and SPEM is often Alcian blue 
positive (Goldenring and Nomura, 2006). Thus, more specific markers are required.  MUC2 
and TFF3 labeling of cells with specific goblet cell morphology provides the most specific 
indication of intestinal metaplasia (Choi et al., 2015; Goldenring et al., 2010).  Notably, 
expression of TFF3 and Muc2 has been reported in lineages with immunocytochemical 
evidence of SPEM, so there may be intermediates of intestinalized SPEM that reflect evolution 
of metaplastic phenotypes (Varon et al., 2012; Weis et al., 2013b).  Expression of nuclear 
Cdx1 and Cdx2 has been noted in human intestinal metaplasia (Kang et al., 2011), but has 
been less apparent in mouse models. 
 
Invasive submucosal glands.  
 The presence of glands penetrating into the submucosa (sometimes referred to as 
gastritis cystica profunda), is usually considered a dysplastic morphology in humans, where 
the presence of GCP has been noted decades after gastrojejunostomy for ulcer disease and is 
considered a pre-neoplastic lesion (Yamaguchi et al., 2001). Intermediate levels of penetrating 
or invasive glands can also be observed.  While this morphology has been reported in H. pylori 
infected Mongolian gerbils, recent investigations have suggested that invasive glands are 
reversible after eradication (Tatematsu et al., 2007). These findings place some of neoplastic 
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implications of invasive submucosal glands in doubt.  In addition, most invasive glands are 
associated with TFF2 expressing mucous cells and often have less proliferation than lesions 
within the mucosa. 
 
Dysplasia.   
 Dysplastic phenotypes are defined my cellular and glandular morphologies on 
hematoxylin and eosin staining.  No specific markers of dysplasia exist.  The interpretation of 
dysplasia is therefore fraught with controversy even among human pathologists.  The situation 
is even more uncertain in mouse models where correlations with cancerous outcomes are 
difficult to assess since there are few instances of cancerous tumors.  Thus it is difficult to build 
key connections between putative dysplastic morphologies and progression to cancer. 
 
Adenocarcinoma.   
 In humans, cells with aberrant, invasive and metastatic characteristics are defined as 
adenocarcinoma.  The aberrant morphologies are generally defined by patterns in hematoxylin 
and eosin staining including multilayered cell patterns (cribiforming) along with altered nuclear 
morphology and positioning.  Proliferative rates are expected to be high, but metaplastic 
lineages also show high proliferative rates.  No present studies have defined specific mutations 
that might define a transition to cancer. 
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Table 1. Markers used to define different stages of metaplasia in the gastric corpus.  
 
   MARKER Normal Stomach Foveolar 
Hyperplasia 
SPEM Intestinalized 
SPEM 
Intestinal 
Metaplasia 
Muc5AC Surface Cell Positive Negative Positive Positive 
UEA1 Surface Cell Positive Negative Negative Negative 
Muc6 Mucous Neck Cell Negative Positive Positive Negative 
GSII Mucous Neck Cell Negative Positive Positive Negative 
Intrinsic Factor Chief Cell Negative Positive Positive Negative 
Chromogranin A Enteroendocrine Cells Negative Negative Negative Negative 
HE4 Not detected Negative Positive Positive Positive 
Phospho-ERK Progenitor Cells Progenitor Cells Positive Positive Positive 
CD44variant Not detected Negative Positive Positive Positive 
Ki67+ SPEM cells Progenitor Zone Negative Negative Positive Negative 
Muc2 Not detected Negative Negative Negative Positive 
TFF3 Not detected Negative Negative Negative Positive 
Cdx1 Not detected Negative Negative Negative Positive 
CFTR Not detected Negative Positive Positive Positive 
Villin Not detected Negative Negative Negative Positive 
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Figure 1. The progression of gastric neoplasia in mice. Gastric corpus cell lineage 
changes observed in the atrophic stomach, with an emphasis on different pathology features 
and cell-specific markers used to distinguish stages of metaplasia. Parietal cell loss disrupts 
normal corpus gland hierarchy and results in the transdifferentiation of chief cells into SPEM.  
SPEM can further progress to intestinalized SPEM and intestinal metaplasia. A. Hematoxylin 
and Eosin images of Ai. Normal gland lineages, Aii. Parietal cell loss and the development of 
foveolar and mucus neck cell hyperplasia, Aiii. Chief cell transdifferentiation into SPEM, Aiv. 
Intestinalized SPEM, Av. intestinal metaplasia. B. Immunofluorescence of different cell-specific 
markers that distinguish pathology features. Bi. normal corpus glands have surface cells 
(UEA1), parietal cells (H/K-ATPase), mucus neck cells (GSII-lectin), and chief cells (gastric 
intrinsic factor, GIF). Bii. Loss of parietal cells is shown through parietal cell marker H/K-
ATPase. The epithelial cells respond through an expansion of mucus neck cells (GSII-lectin) 
and surface cells (UEA1). Biii. SPEM is detected at the base of the glands through double-
positive GSII-lectin and GIF.  The proliferative zone expands throughout the isthmus, however 
SPEM is not proliferative at this stage. Biv. Intestinalized-SPEM is similar to SPEM when 
observed via H&E.  However intestinalized SPEM is highly proliferative, and therefore triple-
positive for GIF, GSII-lectin and Ki67.  Bv. Intestinal metaplasia is indicated through TFF3 
positive enterocytes (shown) and Muc2 positive goblet cells (not shown) with Clusterin (Clu) 
positive cells at the base of glands, indicative of SPEM. C. Cell lineage diagrams highlighting 
pathology features representative of the different stages of metaplasia.  Ci. Normal gastric 
corpus oxyntic gland, with the majority of the epithelial cells types represented: surface cells, 
progenitor cells, parietal cells, mucus neck cells, and chief cells. Cii. The loss of parietal cells 
results in the expansion of surface cells (foveolar hyperplasia) and mucus neck cells (mucus 
neck cell hyperplasia). Ciii. Shortly after parietal cell loss, chief cells transdifferentiate into 
SPEM cells.  Civ. Intestinalized SPEM is proliferative and therefore the number of SPEM cells 
expands upwards into the isthmus.  The visual characteristic of intestinalized SPEM is identical 
to SPEM cells except for the presence of Ki67.  Transcriptome analysis is required to indicate 
intestinalization at this stage. Cv. Intestinal metaplasia is characterized by the presence of 
intestinal cell lineages (enterocytes, goblet cells) interspersed with intestinalized SPEM and 
SPEM cells.  
 
 
2. Human Disease inception and progression 
 The proximate cause of most intestinal type gastric cancer is referable to chronic 
infection with virulent Helicobacter pylori (H. pylori) strains (Correa and Piazuelo, 2012). H. 
pylori is a gram-negative bacteria that inhabits two-thirds of the global population (CDC).  
Chronic H. pylori infection leads to changes in the corpus mucosa that can predispose 
individuals to gastric adenocarcinoma.  These changes result from oxyntic atrophy and chronic 
inflammation. The effect of parietal cell loss is the transdifferentiation of mature zymogen-
secreting chief cells at the base of the fundic glands into spasmolytic-polypeptide expressing 
metaplasia (SPEM). Work over the past several years by our group and others in both humans 
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(Halldorsdottir et al., 2003; Minegishi et al., 2007; Yamaguchi et al., 2001) and rodents 
(Goldenring et al., 2000b; Weis et al., 2013b) has established that SPEM is a common 
metaplastic phenotype observed in the atrophic human and rodent stomach. In the setting of 
inflammation, SPEM is thought to progress into intestinal metaplasia in humans. Pelayo 
Correa originally described the association of intestinal metaplasia with the development of 
intestinal type gastric cancer (Correa, 1988). Thus, metaplastic cell lineages in the stomach 
are recognized as precursors of neoplasia. In addition, intestinal-type gastric cancer, the most 
predominant type of gastric adenocarcinoma, is frequently associated with both SPEM and 
intestinal metaplasia. Whether SPEM or IM gives rise to cancer has yet to be established.  
 
3. Murine models of gastric neoplasia 
 An in depth review of studies over the past 20 years that display SPEM phenotypes in 
association with varying degrees of gastric neoplasia is detailed below: 
 
Helicobacter infection 
 Mice infected with Helicobacter felis recapitulate the pathology associated with 
Helicobacter pylori infection observed in humans, complete with parietal cell loss, inflammation, 
and metaplasia. The mechanism by which Helicobacter causes parietal cell loss actually 
requires the host’s inflammatory response. Roth et al identified that T-cells were necessary for 
Helicobacter associated parietal cell loss, as T-cell deficient mice infected with Helicobacter 
did not develop oxyntic atrophy or metaplasia (Roth et al., 1999). Further studies mouse 
models observed an expansion in TFF2-expressing mucus metaplasia in response to oxyntic 
atrophy (Fox et al., 1996; Wang et al., 1998). The mucus cell lineage expansion was identified 
as SPEM (Schmidt et al., 1999a), which is derived from the transdifferentiation of mature chief 
cells (Nam et al., 2010b).  While SPEM in H. felis-infected mice is highly proliferative 
throughout the metaplastic lineages (Weis et al. 2013), goblet cell intestinal metaplasia is 
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notably absent from mice. However, there is evidence for intestinalization of SPEM during 
chronic H. felis and H. pylori infection (Nomura et al., 2004; Varon et al., 2012; Weis et al., 
2013a).  
 
Acute drug induced models of SPEM 
 A caveat of using Helicobacter infection for studying metaplasia is that alterations, 
especially to the immune system, may affect the competency of Helicobacter to induce oxyntic 
atrophy, a prerequisite for metaplasia development.  Therefore acute drug treatment models 
that induce parietal cell death provides an essential tool to study the inflammatory process in 
metaplasia progression. 
 
Oral administration of DMP-777.  
 Treatment with the parietal-cell specific protonophore drug DMP-777, initially developed 
by Merck, leads to rapid loss of parietal cells within 3 days followed by induction of SPEM after 
10-14 days of treatment (Goldenring et al., 2000b; Nomura et al., 2005b). All of the metaplasia 
is reversible within 7-14 days following cessation of DMP-777 treatment.  Interestingly in both 
mice and rats, administration of DMP-777 for up to 2 years led to prominent continuous 
metaplasia, but never resulted in any dysplastic or neoplastic lesions (Goldenring et al., 2000b). 
The absence of dysplastic lesions in the face of chronic metaplasia appears to be due to a lack 
of inflammation, likely because of the other action of DMP-777 as a cell-permeate elastase 
inhibitor (Goldenring et al., 2000b; Nomura et al., 2005b; Weis et al., 2013a).  
  
3.2.2 Intraperitoneal injections of high doses of tamoxifen.  
 Mice given three consecutive daily doses of 5 mg of tamoxifen have a 90% reduction in 
parietal cell mass in the stomach.  High dose tamoxifen-treated mice develop non-proliferative 
SPEM within 3 days of treatment.  The effect can be reversed after 2-3 weeks following drug 
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withdraw (Huh et al., 2012). The pattern of SPEM induction by high dose tamoxifen resembles 
that induced by DMP-777, although there is evidence for increased levels of inflammation. 
 
Oral administration of L635.  
 L635 is a chiral molecular cousin of DMP-777, which retains parietal cell protonophore 
activity, but lacks the elastase inhibitory capacity (Goldenring et al., 2000b). L635 treatment 
causes rapid induction of parietal cell loss and SPEM in the presence of a prominent 
inflammatory milieu.  The quick oxyntic atrophy combined with a strong inflammatory infiltrate 
in the gastric mucosa leads to accelerated development of a proliferative and intestinalized 
SPEM lineage within 3 days of treatment (Nam et al., 2010a) that is remarkably similar to 
SPEM observed in H. felis (Weis et al., 2013a). M2 macrophages drive the proliferation and 
intestinalization of SPEM in L635-treated mice (Petersen et al., 2014). Therefore L635 
treatment provides a rapid model for the development of proliferative intestinalizing SPEM. 
  
Gastrin Genetic Models 
 Located in the antrum, G cells produce gastrin to promote gland homeostasis by 
regulating acid secretion from parietal cells. Gastrin also functions as a growth factor for ECL 
cells, invasion, angiogenesis, and anti-apoptotic activity at the transcriptional level (Dockray et 
al., 2001).  In the stomach, endogenous gastrin levels increase in response to parietal cell loss 
in order to maximize gastric acid secretion and increase epithelial cell proliferation (Ray et al., 
1996).   
 
Insulin-gastrin (INS-GAS) transgenic mice.  
 The INS-GAS mouse model uses the mouse insulin promoter to drive expression of a 
human gastrin transgene, producing moderate elevations in circulating gastrin levels.  The 
INS-GAS mice on the FVB background develop SPEM and dysplasia, that lead to invasive 
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lesions in the gastric corpus by 20 months of age (Wang et al., 2000b). Metaplastic changes 
are accelerated in the setting of Helicobacter infection, and inhibited by using an H2-histamine 
receptor inhibitor (CITE). These findings suggest that the induction of parietal cell loss resulted 
from a chronic state of acid hyper-secretion. 
 
Gastrin Knockout mice.  
 Gastrin knockout mice develop antral tumors by 12 months of age.  In the corpus, the 
mucosa is generally thinner with fewer parietal cells present.  DMP-777 treatment in gastrin 
knock out mice causes an accelerated induction of SPEM in one to three days, as compared to 
10 days in wild type mice. (Nomura et al., 2005b; Nozaki et al., 2008b). Gastrin knock out 
however do not develop foveolar hyperplasia that typically occurs as a result of oxyntic atrophy, 
consistent with the concept that gastrin is a major driver of foveolar hyperplasia. 
 
Genetic mouse models of parietal cell loss 
Several mouse models induce changes spontaneously consistent with the development of 
SPEM in the corpus of the stomach.  These models may initiate with a normal mucosa and 
then develop increasing levels of atrophy and metaplasia. 
 
Claudin 18 knockout mice.  
 Claudin-18 levels are high in the normal stomach but are prominently reduced in the 
metaplastic stomach (Hayashi et al., 2012). Tsukita and colleagues examined the impact of 
claudin-18 loss in the stomachs of claudin-18 knockout mice (Hayashi et al., 2012). These 
mice displayed few parietal cells at birth and never progressed to normal of parietal cell 
lineages during the postnatal period. Instead claudin-18 knockout mice demonstrated 
proliferative SPEM that was associated with a significant neutrophil infiltrate and elevations in 
IL-1b expression.  The claudin-18 stomachs also demonstrated high levels of the SPEM 
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marker, HE4.  While the metaplastic SPEM lineages in the claudin-18 knockout mice were 
highly proliferative, these mice were only studied up to 16 weeks of age, where no invasive or 
dysplastic lesions were reported. Thus Claudin 18 is necessary for normal parietal cell 
development and therefore gland homeostasis. 
 
KLF4 knockout mice.  
 KLF4 is down-regulated in gastric cancers and loss of KLF4 is associated with poor 
prognosis (Hsu et al., 2013; Wei et al., 2005). In the KLF4 knockout mouse, the stomach 
shows marked oxyntic atrophy from birth and an expansion of both foveolar hyperplasia and 
mucus cell metaplasia (Katz et al., 2005). Some intrinsic factor-expressing cells do remain at 
the bases of corpus glands that are dominated by a TFF2-expressing mucus cell lineage. 
While no dual labeling for intrinsic factor and TFF2 was performed, the staining for TFF2 
appears at the base of the glands, consistent with the suggestion that these glands represent 
SPEM.  Interestingly however, the authors note that there is very little proliferation among the 
SPEM lineages and with observation of mice up to one-year, no intestinal metaplasia, 
dysplasia or invasive lesions developed.  They also noted that no inflammation was 
appreciated.   Thus, this model confirms that concept that SPEM can exist as a stable benign 
metaplasia as was observed in long term administration of DMP-777 (Goldenring et al., 2000b). 
 
H/K-Cholera Toxin mouse.  
 Increased cAMP is the major driver of parietal cell acid secretion mediated through 
activation of the H2-histamine receptor.  Samuelson and colleagues examined a model of 
chronic acid over-production in the H/K-Cholera Toxin mouse (Lopez-Diaz et al., 2006). This 
mouse showed increased acid secretion from an early age, as would be expected for parietal 
cells with increased expression of cholera toxin and cAMP production.  While the mice show a 
normal compendium of cell lineages in the gastric corpus at 2 months of age, by 7 months of 
	   14	  
age the mice develop increasing levels of parietal cell loss and show severe parietal cell loss 
by 15-16 months of age.  The parietal cells loss at the later time points is associated with the 
presence of SPEM.  The loss of parietal cells appears to relate to the development of auto-
antibodies against parietal cell antigens, especially H/K-ATPase.  This model therefore mimics 
the pathogenesis of autoimmune gastritis.  No invasive glands were noted in these mice at the 
later stages although measures of proliferation were not determined. 
 
Models of signaling pathway activation 
 Several studies conducted on characterizing gene and protein expression of metaplasia 
in the murine and human stomach has yet to identify a dominant signaling pathway driving 
neoplasia (Nozaki et al., 2008a; Sousa et al., 2012; Weis et al., 2013a). However different 
signaling pathways aberrations in gastric cancer has been characterized, identifying KRAS, 
FGFR2, EGFR, ERBB2 and MET using single nucleotide polymorphism arrays (Deng et al., 
2012). These and other signaling pathways have been investigated for their role in the 
development of metaplasia and adenocarcinoma. 
 
MAPK/ERK.  
 Up-regulation of phospho-ERK in metaplasia has been noted in both humans and mice.  
However, Ras mutations have only been observed in approximately 9% of gastric cancers.  
Nevertheless, recent gene profiling studies have noted a signature for up-regulation of Kras 
activity in greater than 40% of intestinal type human gastric cancers (Cancer Genome Atlas 
Research, 2014; Tan et al., 2011). Choi, et al. have recently examined the induction of 
metaplasia in Mist1-CreERT2; LSL-KRas (G12E) mice (Choi et al., 2015). Following tamoxifen 
induction, these mice express activated Kras in gastric chief cells, and after 4 weeks 
developed proliferative metaplasia. Two months after induction intestinal goblet cells 
expressing Muc2 are evident, progressing to invasive glands 4 months post induction.  
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Importantly, treatment of the mice with a MEK inhibitor, Selumetinib, caused arrest of the 
metaplasia and allowed recrudescence of normal gastric lineages.  These normal lineages 
were derived from a normal progenitor cell and not the metaplastic lineages.  The normal 
gastric lineages appeared to cause extrusion of the metaplastic glands from the gastric 
mucosa into the lumen.  These findings indicate that activation of Ras is involved at all of the 
key steps in the development of metaplasia, from transdifferentiation of chief cells into SPEM, 
to further differentiation of intestinal metaplasia and the promotion of invasive changes. 
 
TGFb and BMP. 
  Smad3 is a critical signaling protein downstream of TGFb receptor activation.  Smad3 
KO mice were first extensively characterized for the spontaneous development of colonic 
adenocarcinoma (Zhu et al., 1998). While development of colon cancers required colonization 
of animals with Helicobacter hepaticus, observations at the Jackson Laboratories indicated 
that gastric tumors evolved in the absence of any infection.  Detailed analysis of these mice 
subsequently demonstrated that these mice developed SPEM by 6 months of age and invasive 
lesions in the proximal corpus by 10 months of age (Nam et al., 2012). Invasive lesion, thought 
to be derived from the first gland of the corpus, generally showed TFF2-positive cells along 
with large numbers of DCLK1-positive tuft cells. These results suggested that loss of Smad3 
could lead to development of proximal gastric neoplasia. 
 
H/K-Noggin mouse.  
 Todisco and colleagues sought to evaluate the role of BMP signaling in the 
differentiation of gastric lineages in the H/K-Noggin mouse (Shinohara et al., 2010). Inhibition 
of BMP signaling through over-expression of Noggin resulted in reduction of parietal cell 
numbers and expansion of SPEM lineages expressing TFF2.  While there was increased 
proliferation in the mucosa, most of this proliferation was abolished when the transgenic mice 
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were crossed onto gastrin knockout, a finding consistent with a role for proliferation in foveolar 
hyperplasia in these mice rather than SPEM (Todisco et al., 2015). Importantly, the over-
expression of Noggin in the stomach caused an augmentation of metaplastic changes after 
infection with H. felis or H. pylori (Takabayashi et al., 2014). These findings suggest that BMP 
signaling is generally anti-inflammatory and that loss of this signaling may promote metaplasia 
development. 
 
EGFR.  
 The role of EGFR and its ligands in alterations in gastric mucosal lineage differentiation 
has been well established.  Over-expression of TGF-alpha in the gastric corpus is associated 
with severe foveolar hyperplasia in Menetrier’s disease in humans (Dempsey et al., 1992b; 
Nomura et al., 2005a). Over-expression of TGF-alpha in the stomachs of MT-TGF-alpha mice 
leads to a similar phenotype (Goldenring et al., 1996). These studies all suggested that over-
expression of TGF-alpha altered the differentiation of gastric progenitors to the production of 
surface mucus cells over gland cells (e.g. parietal, mucus neck and chief cells). 
 Nevertheless, other studies have suggested that alterations in EGFR activation can 
influence the induction of metaplasia.  Waved-2 mice, which have an attenuating mutation of 
the EGFR, demonstrated enhanced development of SPEM after loss of parietal cells induced 
by DMP-777 (Ogawa et al., 2006). These effects seemed to be specific to particular EGFR 
ligands since although TGF-alpha KO mice showed no alteration in SPEM induction, 
amphiregulin KO mice showed an enhanced induction of SPEM after DMP-777 treatment, 
similar to that observed in waved-2 mice (Nam et al., 2007).  Just as interestingly, 
amphiregulin deficient mice over one year of age developed SPEM spontaneously (Nam et al., 
2009). By 18 months of age, over 40% of amphiregulin knockout mice showed parietal cell loss 
and both SPEM as well as goblet cell intestinal metaplasia.  The goblet cell intestinal 
metaplasia evolved in glands also containing SPEM and cells with intermediate morphology 
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with dual expression of TFF2 and MUC2 observed at the interface between SPEM and 
intestinal metaplasia lineages (Nam et al., 2009). These findings demonstrated that EGFR-
mediated signaling was involved in the evolution of gastric lineages. 
 
Immune-mediated pre-neoplastic mouse models 
Inflammation accompanies most models of metaplasia in the gastric mucosa. Insights into 
different aspects of the inflammatory response reveal the impact of immune cells in the 
progression of metaplasia. 
 
H/K-ATPase-IFNg transgenic mice.  
 The expression of the pro-inflammatory cytokine IFNg, typically expressed by Th1 
polarized T-cells, is increased in Helicobacter infected mice.  Transgenic overexpression of 
IFNg by the parietal cell specific driver H/K-ATPase b promoter causes a prominent 
inflammatory infiltrate, oxyntic atrophy, epithelial cell proliferation and SPEM after 3.5 months. 
SPEM and immune infiltration is still present in Tg- IFNg mice crossed to Rag 1 knock out mice 
that lack T and B cells (Syu et al., 2012). Therefore IFNg alone can drive gastric metaplastic 
changes without the assistance of polarized T or B cells.  
  
Hip1r and IFNg double knockout mice.  
 Huntington interacting protein 1 is required for normal parietal cell maturation (Jain et al., 
2008). Parietal cells undergo apoptosis in Hip1r knock out mice and develop a robust 
inflammatory response and SPEM by 12 months of age. Double Hip1R and IFNg knock out 
mice have delayed metaplasia development, but mice 12 months of age appear to have similar 
phenotypic SPEM as control Hip1R knock out mice.  Therefore, IFNg is not required for SPEM 
induction after parietal cell loss (Liu et al., 2012).  
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TxA23 mice. 
  Human autoimmune gastritis occurs when T-cells target parietal cells for apoptosis in 
the stomach, causing robust metaplasia that predisposes affected individuals to endocrine 
carcinoids (Solcia et al., 1992). Transgenic mice engineered with CD4+ T-cells that recognize 
the parietal specific antigen H/K-ATPase crossed on to the BALB/c background develop SPEM 
by 2-4 months of age.  By 12 months of age, TxA23 mice have extensive inflammation with 
areas of aberrant gland morphology and penetrating submucosal glands (Nguyen et al., 2013). 
The severity of phenotype observed in this model may be attributed to the BALB/c background, 
which is considered a Th2 dominant background (Hsieh et al., 1995; Watanabe et al., 2004). 
Specifically, T-cells in BALB/c mice express higher levels of IL-4 than IFNg that drives a Th2 
response. Most investigations in the stomach use C57Bl/6 mice, which is considered a Th1 
dominant background where T cells express higher levels IFNg. Therefore the severity of 
metaplasia in the TxA23 atrophic gastritis model is perhaps indicative of a Th2 driven 
environment paired with parietal cell loss. 
 
H/K-ATPase IL-1b transgenic mice.   
 Polymorphisms in the IL-1 beta gene are observed in a variety of human, including 
gastric adenocarcinoma.  Il-1b is part of the IL-1 family of cytokines that function as alarmins 
by promoting the inflammatory response. Il-1b expression increases in Helicobacter infections 
and is also associated with myeloid cell infiltration. Transgenic mice expressing human Il-1b by 
parietal cells using the H/K-ATPase promoter develop spontaneous inflammation, oxyntic 
atrophy, and SPEM with dysplastic lesions at late time points.  Helicobacter increases the 
susceptibility and speed at which gastric pathology develops in Tg Il-1b mice (Tu et al., 2008). 
Conversely, IL-1 receptor antagonist treatment can inhibit the progression of metaplasia and 
inflammatory cell infiltration.  Together these findings support Il-1b as a major driver of 
inflammatory cell recruitment that promotes the progression of metaplasia. 
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Sdf1 Transgenic mice.  
 Stromal derived factor 1 (SDF1) is typically expressed by cancer-associated fibroblasts 
and found upregulated in Helicobacter-infected gastric mucosa. Transgenic mice expressing 
SDF-1 from parietal cells using the H/K ATPase driver do not have recruitment of inflammatory 
cells, however display hyper-proliferative gastric epithelial cells and focal areas of SPEM with 
dilated glands at late time points (18 months). H. felis infected SDF1-Tg mice develop 
accelerated pathology.  And similarly when Tg-SDF1 mice are crossed to pro-inflammatory Tg-
IL1b mice there is increased epithelial cell proliferation and accelerated SPEM development in 
the corpus (Shibata et al., 2013). These data indicates that while SDF1 does not drive 
recruitment of inflammatory cells, it does appear to promote epithelial changes and promote 
SPEM, especially in the setting of atrophic gastritis. 
 
K19-C2mE mice.  
 Cox2 is frequently overexpressed in gastric cancer. Oshima et al developed transgenic 
mice expressing Cox-2 and mPGES-1 in progenitor cells, driven by the cytokeratin 19 
promoter (CITE). These effects cause M2 polarized macrophages to be recruited into the 
mucosa, subsequently causing the development of SPEM.  After 80 weeks, these mice 
progress to develop hyperplastic tumors. Treatment using the non-steroidal anti-inflammatory 
drug meloxicam ameliorates the inflammation and reverses the metaplastic gland morphology. 
In an effort to determine the role of specific cytokines in this process, TNFa and IL1r1 knock 
out mice were crossed on to the K19-C2mE.  Mice null for TNFa had decreased inflammation, 
reducing metaplasia overall.  However no overt change in inflammation or metaplasia was 
observed in IL1r1 null mice.  Therefore Cox2 and PGE2 can drive metaplastic changes in the 
stomach through the recruitment of M2 polarized macrophages in a TNFa-dependent 
pathway (Oshima et al., 2005).  
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Gan mice. 
  Activated b-catenin activity, however not mutations in APC, is observed in 51% of 
human intestinal type gastric cancers (Oshima et al 2006). K19 progenitor cells driving Wnt1 
expression cause suppression of normal gastric epithelial cell differentiation that is 
accompanied with increased proliferation and TFF2 positive cells. By 7 to 18 weeks mice 
develop small preneoplastic lesions in the corpus. The Gan mice were developed by crossing 
K19-Wnt1 mice to K19-C2mE mice (described above), thereby activating Wnt signaling in 
progenitor cells with a coordinated immune cell infiltration. This results in exacerbated 
metaplasia that drives the rapid development of gastric dysplasia and tumors in the corpus. 
Furthermore, amelioration of the inflammatory response using a CCL2 chemokine inhibitor or 
clodronate treatment to deplete macrophages causes tumor regression in Gan mice (Oshima 
et al., 2011a). Thus activation of the Wnt signaling pathway can drive metaplasia formation but 
inflammation is necessary for metaplasia progression.  
 
Exogenous IL-11 treatment. 
  IL-11 belongs to the IL-6 family of cytokines that induces signal transduction through 
the IL-11Ra. IL-11 is not expressed during the early stages of an inflammatory response 
associated with Helicobacter infection, but gradually increases during chronic inflammation and 
intestinal metaplasia.  While IL-11 expression is normally localized to parietal cells, this is 
subsequently lost in the setting of oxyntic atrophy in response to Helicobacter infection.  
Therefore the source of increased IL-11 expression in chronic Helicobacter infection originates 
elsewhere.  Nevertheless, exogenous treatment of IL-11 in wild-type mice leads to parietal cell 
loss within 24 hours, an infiltration of polymorphonuclear cells, and the emergence of SPEM 
(Howlett et al., 2012).  Thus, it is hypothesized that IL-11 is released by dying parietal cells to 
recruit inflammatory cell into the stomach and promote the development of SPEM. 
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Exogenous IL33 treatment.  
 A member of the IL-1 family of cytokines, IL-33 is expressed normally in the gastric 
mucosa, localizing to cells in the surface cell zone.  IL-33 synergizes to promote a Th2 
inflammatory response that activates innate and adaptive immune cells. Several studies refer 
to IL-33 as an alarmin due to its release into the extracellular environment by necrotic or 
apoptotic cells.  IL-33-treated mice develop mucus metaplasia and a robust inflammatory 
response in the lungs, intestine and stomach, indicating that IL-33 is sufficient to recruit 
inflammatory cells and drive mucus production within respiratory and gut epithelial tissue 
(Buzzelli, 2015; Pastorelli et al., 2013). However, IL-33 is only expressed in the normal 
stomach by cells in the surface cell zone in the corpus, which do not undergo cell death during 
Helicobacter infection.  Therefore while administration of IL-33 is capable of recruiting 
inflammatory cells and inducing SPEM, it is remains to be seen if endogenous IL-33 functions 
in this capacity. 
 
5. Conclusions 
 Data from mouse models indicates that the induction of metaplasia involves at least two 
phases.  Induction of metaplasia first requires the loss of parietal cells.  Parietal cell loss 
induced by Helicobacter infection requires the action of specific lymphocytic populations and 
specific immune modulatory molecules.  In a second phase, following the loss of parietal cells, 
SPEM develops from transdifferentiation of chief cells.  However, expansion of the metaplasia 
requires the chronic influence of M2-macrophage subclasses.  The utilization of a number of 
drug-induced methods to ablate parietal cells acutely can bypass the first chronic phase 
required for parietal cell loss.  Similarly, genetic models, such as directed activation of Ras in 
chief cells, directly induced transdifferentiation of chief cells and promote inflammatory 
regulators required for expansion of metaplasia.  Mouse models of immune modulator over-
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expression can similarly induce both parietal cell loss and SPEM induction.  It seems evident 
that inflammatory mediators and/or MDSCs are required for induction of more aggressive and 
proliferative metaplasia that can progress to dysplasia.   
 What remains unclear from mouse models is a clear connection with the latter stages of 
carcinogenesis.  Most models interrogate the initiation of metaplasia and none of the models 
can induce clear metastatic or even regionally invasive adenocarcinoma.  Indeed, many of the 
lesions that are labeled as “dysplastic” seem over-interpretations of metaplastic or reactive 
lesions.  With the exception of the Mist1-Ras mouse and some older amphiregulin KO mice, 
mouse models of metaplasia have not faithfully recapitulated the induction of goblet cell-
containing intestinal metaplasia.  Given the presence of invasive lesions derived from SPEM in 
a number of the mouse models, this may suggest that intestinal metaplasia may represent an 
adaptive response to chronic injury rather than a true preneoplastic lesion.  Further studies are 
therefore needed to discern the molecular mediators of key transition points along the 
metaplasia to carcinoma sequence: at the point of transdifferentiation of chief cells into SPEM, 
at the transition of SPEM into intestinal metaplasia and at the point of true dysplastic transition 
from metaplasia (SPEM or intestinal metaplasia). 
 
4. Aims  
 Recent studies have thus allowed the proposal of a paradigm that unifies our knowledge 
of metaplasia in mice and humans. It seems likely that the initiating event in metaplastic 
induction in both mice and humans is a loss, either acutely or chronically, of acid-secreting 
parietal cells.  The loss of parietal cells triggers the transdifferentiation of chief cells into SPEM 
(Nam et al., 2010a). In the setting of local injury to the mucosa, this type of response would 
provide a mechanism for local repair of mucosal defects.  Thus, induction of SPEM as a 
primary metaplasia may be inherently reparative and reversible. Nevertheless, in both human 
and mouse SPEM, the presence of inflammatory infiltrates appears to lead to an increasingly 
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proliferative metaplasia as well as progression towards more intestinalized metaplastic 
phenotypes.  While in humans this process culminates in the development of a fully 
intestinalized mucus cell phenotype (intestinal metaplasia), SPEM in mice acquires 
intestinalizing characteristics under the influence of inflammation without complete phenotypic 
changes characteristic of goblet cell intestinal phenotypes (Varon et al., 2012; Weis et al., 
2013b). Intestinalized proliferative SPEM in mice is emblematic of the progression to an 
advanced metaplastic phenotype. Nevertheless, the influences responsible for the expansion 
of this metaplasia to a more proliferative phenotype and its further differentiation into a more 
intestinalized metaplasia remain obscure. Previous data suggest that inflammation is driving 
this process forward. The following chapters will provide definitive data implicating M2a 
macrophages producing IL-33 as the driving force behind metaplasia development and 
progression. 
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Chapter II 
MACROPHAGES PROMOTE PROGRESSION OF SPASMOLYTIC POLYPEPTIDE 
EXPRESSING METAPLASIA (SPEM) FOLLOWING ACUTE PARIETAL CELL LOSS 
 
Appear as: Christine P. Petersen, Victoria G. Weis, Ki Taek Nam, Josane F. Sousa, Barbara 
Fingleton and James R. Goldenring. Macrophages promote progression of spasmolytic 
polypeptide expressing metaplasia (SPEM) following acute parietal cell loss. Gastroenterology. 
146(7):1727-38. 2014 
 
Introduction 
 
Gastric adenocarcinoma is the second highest cause of cancer-related death in the world (de 
Martel et al., 2012). Due to a lack of early clinical manifestations, gastric cancer frequently 
presents as late stage disease. Helicobacter pylori (H. pylori) infection is the major 
predisposing factor for gastric cancer, causing chronic inflammation and oxyntic atrophy in the 
gastric mucosa (Blaser and Parsonnet, 1994). The parietal cell loss disrupts the homeostatic 
glandular environment and chief cells transdifferentiate into spasmolytic polypeptide 
expressing metaplasia (SPEM) (Nam et al., 2010b; Weis et al., 2013a). Increasing data 
suggest that intestinal metaplasia (IM) arises from SPEM in humans, supporting the 
hypothesis that SPEM is the critical initial pre-neoplastic metaplasia predisposing to gastric 
adenocarcinoma (Goldenring et al., 2010; Nam et al., 2009; Yoshizawa et al., 2007). 
Helicobacter felis (H. felis) infection in mice recapitulates the inflammatory and pre-neoplastic 
cascade of human H. pylori infection (Nam et al., 2010b). In the murine Helicobacter infection 
model, SPEM develops after 6 to 12 months of infection. As in human infection with H. pylori, 
there appear to be two phases in the development of metaplasia.  First, the infection induces 
parietal cell loss or oxyntic atrophy. Oxyntic atrophy is required for the induction of metaplasia 
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in humans (El-Zimaity et al., 2002; Meining et al., 2001). In the presence of on-going 
inflammation, metaplasia then evolves and expands.  Given the long latency for SPEM 
development in H. felis-infected mice, our group developed two acute SPEM models.  The 
administration of either drugs DMP-777 or L635 induces SPEM by selectively ablating parietal 
cells (Goldenring et al., 2000a; Nomura et al., 2005b). Mice treated with DMP-777 for 14 days 
develop SPEM without the presence of significant inflammation, likely due to the ability of 
DMP-777 to also inhibit elastase activity (Goldenring et al., 2000a). In contrast, L635-treated 
mice develop an advanced proliferative SPEM with intestinal characteristics (previously 
designated as SPEM-IC) in just 3 days of treatment which is associated with both loss of 
parietal cells and a prominent inflammatory infiltrate (Nam et al., 2010b; Weis et al., 2013a).  
The phenotype of mice treated L635 for 3 days is similar to that for mice infected with H. felis 
for 6 months or more (Weis et al., 2013a). Thus, the L635 model appears to bypass the initial 
phases of H. felis infection that leads to oxyntic atrophy by directly inducing parietal cell loss 
acutely.  While mice do not develop typical goblet cell intestinal metaplasia in either the L635-
treatment or Helicobacter infection models, they do develop advanced proliferative SPEM that 
is characterized by the expression of specific upregulated intestinal transcripts (Cftr, Dmbt1 
and Gpx2) and an increase in proliferative SPEM cells (Houghton et al., 2004; Wang et al., 
2000a; Weis et al., 2013a).  Similarly, Varon et al. observed an increase in intestinal 
characteristics in murine metaplasia associated with long-term Helicobacter infection (Varon et 
al., 2012). Studies with DMP-777 treatment demonstrate that loss of parietal cells even without 
inflammation leads to the development of SPEM from transdifferentiation of chief cells; 
however, the presence of inflammation in L635-treated mice leads to more rapid SPEM 
induction as well as promotion of both increased proliferation and a more intestinalized 
phenotype . Thus, inflammation is a key factor in the advancement of SPEM to a more 
aggressive metaplastic phenotype.  Nevertheless, the precise immune cell populations 
responsible for the progression of metaplasia are not known. 
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Four distinct inflammatory cell populations are most frequently associated with Helicobacter 
infection in the stomach: B-cells, interferon-γ (IFNγ) secreting T-cells, neutrophils, and 
macrophages (Fox et al., 1993). Through the manipulation of specific immune cells, previous 
studies have shown that T-cells contribute to parietal cell loss and the development of 
metaplasia in Helicobacter infection (Roth et al., 1999). However, chronic inflammation 
associated with Helicobacter infection is predominately made up of neutrophils and 
macrophages. These phagocytic cells migrate into the mucosa to engulf debris and propagate 
the inflammatory response (Chow et al., 2011). Similarly, during acute induction of SPEM with 
L635, there is a significant influx of T-cells, B-cells, neutrophils and macrophages that migrate 
into the mucosa (Nam et al., 2010b). Still, little is known about which immune cells promote the 
advancement of SPEM. 
In the present studies, we have sought to assess the influence of specific immune cell 
populations on the advancement of SPEM following the induction of parietal cell loss.  To 
address the specific immune components, we evaluated the presence and characteristics of 
L635-induced SPEM in various mouse models of depleted immune cells.  Rag1 knockout mice 
(Rag1KO) deficient in T- and B-cells, IFNγ knockout mice (IFNγKO), neutrophil-depleted mice 
(Ly6G antibody-treated), and macrophage-depleted mice (clodronate-treated) were each 
administered L635 to induce acute parietal cell loss and SPEM.  Our findings indicated that M2 
macrophages are the critical immune cell driver of the induction of metaplasia following loss of 
parietal cells. 
 
Methods 
Treatment of Animals 
L635 treatment 
Each experimental group consisted of three male mice. L635 (synthesized by the Chemical 
Synthesis Core of the Vanderbilt Institute of Chemical Biology), dissolved in deionized DNA 
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and RNA-free water, was administered by oral gavage (350 mg/kg) once a day for three 
consecutive days.  Neutrophils were depleted through intraperitoneal injection of anti-Ly6G 
antibody (Leaf, BioLegend, San Diego, CA) (100 µg) two days prior to and throughout the 
three day L635 administration. Control mice received intraperitoneal injections of a non-
specific isotype-matched IgG antibody.  Macrophages were depleted by intraperitoneal 
injection of clodronate-containing liposomes (Encapsula NanoSciences, Brentwood, TN) (10 
mg/kg) two days prior to and throughout the three days of L635 administration. Control mice 
received liposomes alone (10 mg/kg).  Mice were sacrificed on the third day of L635 
administration. 
 
DMP-777 treatment 
Three male mice were used for each experimental group. DMP-777 (a gift from DuPont-Merck 
Co.) dissolved in 1% methylcellulose was administered by oral gavage (350mg/kg) once a day 
for 8 consecutive days. Macrophages were depleted using four intraperitoneal injections of 
clodronate-containing liposomes (10 mg/kg) every other day of DMP-777 treatment.  Control 
mice received liposomes (10 mg/kg) with or without DMP-777-treatment. Mice were sacrificed 
the ninth day. 
 
Immunohistochemistry 
Stomachs from mice were fixed in 4% paraformaldehyde overnight and transferred into 70% 
ethanol for subsequent paraffin embedding.  Five µm sections were used for all 
immunohistochemistry studies.  Sections were deparaffinized and rehydrated.  Target 
Retrieval Solution (DakoCytomation, Glostrup, Denmark) was used for antigen retrieval in a 
pressure cooker. Slides were blocked using Protein Block Serum-free (DakoCyomation) for 
one hour at room temperature.  The following primary antibodies were incubated at 4°C 
overnight in Antibody Diluent with Background Reducing Components (DakoCyomation): goat 
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anti-intrinsic factor (1:1000, a gift from Dr. David Alpers, Washington University, St. Louis, MO), 
rat immunoglobulin G (IgG) anti-Ki-67 (1:500; Dako), rat anti-F4/80 (1:500; Invitrogen, Grand 
Island, NY), rat anti-mouse Ly6B.2 (1:500; AbD Serotec, Oxford, UK), goat anti-Arginase II 
(1:100; Santa Cruz, Dallas, TX), rabbit anti-CD68 (1:200; Abbiotec, San Diego, CA), mouse 
anti-iNos (1:300; Abcam, Cambridge, MA), mouse anti-CD163 (1:200; NeoMarkers, Fremont, 
CA), mouse anti-human CD68 (1:5,000; Dako).  Fluorescent secondary antibodies (1:500) and 
Alexa 488 and 647-conjugated Griffonia simplicifolia lectin II (GSII-lectin) (1:1500; Molecular 
Probes, Eugene, OR) were incubated for one hour at room temperature for detection. Sections 
were analyzed using a Zeiss Axiophot microscope equipped with an Axiovision digital imaging 
system (Zeiss, Jena GmBH, Germany) or an Ariol SL-50 automated slide scanner (Leica 
Biosystems, Buffalo Grove, IL, USA) in the Vanderbilt Digital Histology Shared Resource. 
 
Quantitative real-time PCR 
Total RNA from the fundus was extracted from paraformaldehyde-fixed paraffin-embedded 
(FFPE) tissue of three male mice per group to examine the expression of intestinal transcripts 
(Cftr, Dmbt1, Gpx2).  Five µm sections were taken for H&E stain to identify fundic areas in the 
tissue blocks.  A 2 mm biopsy punch was then used to extract fundic tissue. The standard 
Qiagen RNeasy FFPE kit protocol was used for purification of total RNA and DNAse treatment. 
A mirVana PARIS kit (Ambion) was used to extract total RNA from fresh whole fundus to 
assess M1 and M2 macrophage transcript expression. One µg of RNA was DNAse-treated 
(Promega) and used for cDNA synthesis using Superscript III Reverse Trascriptase 
(Invitrogen).  Quantitative real-time polymerase chain reaction (qRT-PCR) was performed with 
EXPRESS SYBR GreenER qPCR SuperMix (Invitrogen) and specific primers in an ABI 
StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA).  All samples 
were run in triplicate following the SYBR Green Supermix manufacturer’s protocol.  The 
expression of TATA-box binding protein (TBP) was used as an endogenous control for 
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normalization and the 2-ΔΔ method was used to compare samples when assessing the 
expression of the intestinal transcripts Cftr, Dmbt1, Gpx2.  Statistical significance (p<0.05) 
between the groups was determined using the Mann-Whitney U one-tailed or two-tailed test.  
The primer sequences used have been previously reported (Cftr, Dmbt1, Gpx2, Tbp, TNFα, 
IL10, IL4, IFNγ).(Nam et al., 2009; Weis et al., 2012) Additionally specific IL-1b primers were 
used: forward AAATGCCACCTTTTGACAGTG and reverse GGCAGTATCACTCATTGTGGC.  
Primers for M1 and M2 macrophage marker primers: Ym1 (Chi3L3), Fizz1 (Resistin-like alpha, 
Retnla), ArgI, Nos2, Cd3, and Cxcl10 (QuantiTect Primer Assay, Qiagen), were used per the 
manufacturer’s protocol with EXPRESS SYBR GreenER qPCR mix on the ABI StepOnePlus 
Real-Time PCR System. The expression of the M1 and M2 markers was normalized to 
GAPDH expression (QuantiTect Primer, Qiagen) and displayed as expression levels (2-ΔCt), 
multiplied by a 1000. 
 
Quantitation of proliferative SPEM and immune cells 
Images were analyzed using CellProfiler or manually counted.(Jones et al., 2008) Each 
experimental group contained three mice. Five representative images were taken for each 
mouse at 20X, and the cells of interest in each image were counted. SPEM cells were 
identified as gastric intrinsic factor and GSII-lectin co-positive cells.  Ki67 was used to identify 
proliferative cells.  SPEM proliferation was identified through Ki67, intrinsic factor, and GSII-
lectin triple-positive cells, and quantitated by counting the number of triple-positive cells on 
each 20X field image.  Neutrophils and macrophages were labeled using specific markers and 
both counted in five images per mouse in a 20X field image.  For all cells counted, nuclei were 
present as detected by DAPI.  The Mann Whitney U one tailed Test was used to calculate 
statistical significance (p<0.05). The inflammatory infiltrate in human metaplasia was assessed 
using sections from a tissue array(Leys et al., 2007) containing normal and metaplastic gastric 
tissue.  Samples were stained for macrophage markers CD68 (general macrophage) or CD163 
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(M2 macrophage) in serial sections and co-labeled with GSII-lectin.  Each core was scanned 
using an Ariol SL-50 automated slide scanner at 20X, and the cells of interest were counted 
using Cell Profiler.  At minimum, three cores from each group were counted. 
 
Results 
Rag1 and IFNγ knockout mice develop acute proliferative SPEM 
To determine the role of the adaptive immune system in the development of proliferative 
SPEM, wild type, Rag1KO and IFNγKO mice were administered L635 for three days and 
stomach cell lineages were analyzed.  Histologic examination revealed parietal cell loss and 
significant inflammatory infiltration in the fundus of the stomach in all L635-treated mice (Figure 
1).  Upon L635 treatment, neutrophils increased by 6-fold in wild type mice, with no significant 
difference observed in L635-treated Rag1KO or IFNγKO mice (Figure 2A and C).  F4/80 
positive cells increased three to five-fold in wild type, Rag1KO, and IFNγKO L635-treated mice 
compared to untreated mice (Figure 2B and C).  L635-treated Rag1KO and IFNγKO mice did 
not have a significant change in F4/80 positive cells compared to wild-type L635-treated mice 
(Figure 2C).  L635-treated Rag1KO and IFNγKO mice developed SPEM (as defined by 
intrinsic factor and GSII-lectin co-positive cells),(Liu et al., 2012) similar to L635-treated wild-
type mice (Figure 3A and C).  Furthermore, L635-treated Rag1KO and IFNγKO mice showed a 
40 to 50-fold increase in SPEM cell proliferation similar to wild-type L635-treated mice (as  
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Figure 2: Effective parietal cell loss after L635 administration in wild type, Rag1KO and 
IFNγKO mice.  A. Hematoxylin and eosin staining of untreated and L635-treated wild-type 
fundus.  B. Staining of normal and L635-treated Rag1KO fundus. C. Staining of normal and 
L635-treated IFNγKO mice. Scale bars: 50 µm. 
  
	   32	  
 
 
Figure 3: Wild type, Rag1KO and IFNγKO mice have similar recruitment of neutrophils 
and macrophages after L635-treatment. A. Immunofluorescence staining with antibodies 
against Ly6B.2 (red) to label neutrophils co-labeled with GSII-lectin (green) and DAPI (blue) 
staining in untreated and L635-treated wild type, Rag1KO and IFNγKO mice. B. 
Immunofluorescence staining with antibodies against F4/80 (red) to label macrophages and 
dendritic cells co-labeled with GSII-lectin (green) and DAPI (blue) staining.  C. Quantitation of 
the total number of neutrophils and F4/80 positive cells counted per 20X field.  L635-treated 
wild type, Rag1KO and IFNγKO mice all showed a significant increase in neutrophils and 
macrophages (*p=0.05) compared to untreated controls.  There was no significant difference in 
neutrophil or F4/80 positive cell numbers between wild type mice compared to either Rag1KO 
or IFNγKO treated with L635 (Mann Whitney U two-tailed Test). Scale bars: 50 µm. 
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Figure 4: Wild type, Rag1KO and IFNγKO mice develop acute proliferative SPEM after 
L635-treatment. A. Immunofluorescence staining for SPEM using gastric intrinsic factor (GIF) 
in red co-labeled with GSII-lectin (green) and DAPI (blue).   GSII-lectin and GIF co-positive 
cells at the base of the glands were considered SPEM. B. Immunofluorescence staining for 
proliferation using Ki67 (red) co-labeled with GSII-lectin (green) and DAPI (blue) to determine 
the presence of SPEM cell proliferation before and after L635 administration in wild type, 
Rag1KO and IFNγKO mice. Ki67, GIF, and GSII-lectin triple-positive cells were considered 
proliferative SPEM.  C. Quantitation of GSII+ and GIF+ cells (SPEM) and proliferative SPEM 
cells in wild type, Rag1KO and IFNγKO mice, (*p=0.05). D. qPCR of advanced proliferative 
SPEM markers. All L635-treated mice showed significant increases in the expression in 
intestinal transcript markers Cftr, Dmbt1 and Gpx2 (*p=0.05). Scale bars: 50 µm. 
 
defined by Ki67, gastric intrinsic factor, and GSII-lectin triple-positive cells) (Figure 3B and 1C).  
To determine whether Rag1KO or IFNγKO mice develop advanced proliferative SPEM, the 
expression of SPEM-associated intestinal transcripts was analyzed by qRT-PCR (Figure 3D).  
Cftr, Dmbt1, and Gpx2 expression was significantly upregulated (55-fold, 30-fold, and 7-fold, 
respectively) in L635-treated Rag1KO mice (Figure 3D).  L635-treated IFNγKO mice showed 
similar changes in Cftr, Dmbt1 and Gpx2 expression comparable to changes observed in 
L635-treated wild type (Figure 3D).  These results all indicate that the presence of T- and B-
cells or IFNγ is not necessary for the development of advanced proliferative SPEM after acute 
parietal cell loss. 
 
Neutrophil-depleted mice develop acute proliferative SPEM 
Neutrophils are potent phagocytic cells that are recruited to the gastric fundus in L635-treated 
mice (Nam et al., 2010b). Neutrophils were depleted in mice using an anti-Ly6G antibody to 
determine the role of neutrophils in the development of SPEM (Daley et al., 2008).  Control 
mice were dosed with a matched anti-IgG, and L635 was administered to both groups of mice.  
Prominent parietal cell loss and inflammation were observed by H&E within the fundic mucosa 
of all mice (Figure 4A).  Immunostaining for Ly6B.2, a neutrophil and polymorphonuclear cell 
marker, confirmed effective depletion of neutrophils in L653-Ly6G-treated mice compared to 
control L635-IgG-treated mice (Figure 4B and D).  Macrophage and dendritic cells labeled by 
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F4/80 antibody were not significantly altered by neutrophil depletion (Figure 4C and D). The 
number of SPEM cells increased five-fold, while SPEM cell proliferation increased 40 to 50-fold, 
in both neutrophil-depleted and control L635-treated mice (Figure 5A, B, and C).  Quantitative 
PCR for intestinal transcripts revealed a significant upregulation of Cftr, Dmbt1 and Gpx2 in 
both neutrophil-depleted and control L635-treated mice (Figure 5D). These results indicate that 
neutrophils are not necessary for the development of acute advanced proliferative SPEM. 
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Figure 5: Effective neutrophil depletion did not significantly alter macrophage 
recruitment. A. Hematoxylin and eosin staining of control and neutrophil-depleted mice. B. 
Immunofluorescence staining of neutrophils with antibodies against Ly6B.2 (red) co-labeled 
with GSII-lectin (green) and DAPI (blue) in mice treated with either control IgG or anti-Ly6G to 
deplete neutrophils. Note the effective depletion of neutrophils with anti-Ly6G treatment. C. 
Immunofluorescence staining of macrophages and dendritic cells with F4/80 (red) antibody co-
labeled with GSII-lectin (green) and DAPI (blue) in mice treated with either control IgG or anti-
Ly6G. D. Quantitation of the total number of neutrophils and macrophages counted per 20X 
field.  IgG-L635-treated mice had a significant increase in neutrophils (*p=0.05) compared to 
controls. Neutrophils were decreased significantly in mice treated with both anti-Ly6G and 
L635 (*p=0.05) compared to anti-IgG-L635-treated mice. Macrophages significantly increased 
in all L635-treated mice (*p=0.05). Macrophage recruitment following L635 treatment was not 
significantly altered after neutrophil depletion. Scale bars: 50 µm 
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Figure 6: Neutrophil-depletion in mice does not alter the development acute advanced 
proliferative SPEM after L635 treatment. A. Immunofluorescence staining of SPEM cells 
with antibodies against GIF (red) co-labeled with GSII-lectin (green) and DAPI (blue) in mice 
treated with either control anti-IgG or anti-Ly6G. B. Immunofluorescence staining of 
proliferating cells with antibodies against Ki67 (red) co-labeled with GSII-lectin (green) and 
DAPI (blue), in untreated or L635-treated mice administered either control anti-IgG or anti-
Ly6G to deplete neutrophils. C. Quantitation of GSII+ and GIF+ cells (SPEM) and proliferative 
SPEM cells per 20X field.  IgG-L635-treated mice had a significant increase in SPEM cells and 
proliferative SPEM cells (*p=0.05) compared to anti-IgG untreated mice.  In mice treated with 
anti-Ly6G and L635 we observed significant increases in SPEM cells and proliferative SPEM 
cells (*p=0.05) compared to anti-Ly6G untreated mice. D. qPCR of intestinal transcript markers.  
All L635-treated mice showed similar increases in Cftr, Dmbt1 or Gpx2 expression (*p=0.05). 
Scale bars: 50 µm. 
 
 
Macrophages are involved in the development of acute L635-induced SPEM 
Macrophages make up a significant portion of the inflammatory infiltrate in L635-treated mice 
(Nam et al., 2010b). Therefore, we evaluated the impact of macrophage depletion using 
clodronate on the development of SPEM induced by L635.  Mice were treated with either 
clodronate-containing liposomes or control liposomes without clodronate for two days prior to 
and throughout the three days of L635 administration.  All L635-treated mice showed 
significant parietal cell loss (Figure 6A). Mice treated with L635 and either control liposomes or 
clodronate demonstrated a 10 to 15-fold increase in neutrophils (Figure 6B and D).  Therefore 
neutrophil recruitment was not significantly affected by macrophage depletion (Figure 6D). 
The antibody F4/80 was utilized to identify macrophages and dendritic cells to confirm 
macrophage depletion by clodronate treatment.  In untreated mice an average of 50 tissue-
resident macrophages and/or dendritic cells was observed per 20X field (Figure 6C). These 
resident immune cells serve to alert the host to invading pathogens and to clear dead cells 
(Chow et al., 2011). After L635 administration, F4/80 positive cells increased three-fold in 
control mice; however, the number of F4/80 positive cells in the gastric fundic mucosa of 
clodronate-L635-treated mice remained unchanged and similar to untreated mice (Figure 6C 
and D). These findings suggest that clodronate-containing liposomes depleted systemic 
macrophages, but not tissue-resident macrophages or dendritic cells in the stomach. 
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Figure 7: Clodronate treatment reduced the influx of macrophages into the fundic 
mucosa after L635 treatment.  A. Hematoxylin and eosin staining of control (liposome-
treated) and macrophage-depleted (clodronate-treated) mice. B. Immunofluorescence staining 
of neutrophils with antibodies against Ly6B.2 (red) co-labeled with GSII-lectin (green) and 
DAPI (blue) in mice treated with either control liposomes or clodronate to deplete 
macrophages. C. Immunofluorescence staining of macrophages with antibodies against F4/80 
(red) co-labeled with GSII-lectin and DAPI in mice treated with either control liposomes or 
clodronate. D. Quantitation of total numbers of neutrophils and macrophages counted per 20X 
field. Neutrophils increased significantly in both control and macrophage-depleted L635-treated 
mice (*p=0.05).  Neutrophil numbers were not significantly affected in mice treated with both 
clodronate and L635.  Note that macrophage recruitment into the fundic mucosa was inhibited 
in mice treated with both clodronate and L635 (*p=0.05). Scale bars: 50 µm. 
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After L635 administration, control mice showed a five-fold increase in SPEM cells, while 
clodronate-treated mice L635 elicited only a two-fold increase in the number of SPEM cells 
(Figure 7A and C).  Furthermore, SPEM cell proliferation increased 40-fold in control L635-
treated mice, but only 10-fold in mice treated with both clodronate and L635 (Figure 7B and C).  
Therefore, macrophage depletion significantly attenuated the number of SPEM cells per gland 
and the proliferative response in SPEM following L635 administration (Figure 7A, B, and C).  
Notably, mice treated with both clodronate and L635 demonstrated significantly lower levels of 
intestinal transcripts for Cftr, Dmbt1 and Gpx2 compared to the L635-treated control mice 
(Figure 7D). 
 We have previously shown that IL-1β and IL10 expression significantly increases in 
SPEM associated with inflammation (Nam et al., 2010b). Thus, we sought to evaluate how 
depletion of macrophages might affect these specific cytokine levels.  As previously noted 
(Nam et al., 2010b), control mice demonstrated a significant increase in IL-1β following L635 
administration (Figure 7E). However, IL-1β cytokine expression was significantly reduced in 
clodronate-L635-treated mice compared to L635-treated mice (Figure 7E).  In contrast, 
clodronate treatment had no significant effect on TNFα or IL10 expression, which can be 
produced by other cells besides macrophages. IFNγ and IL4 were undetectable in all samples 
(data not shown). 
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Figure 8: Macrophage depletion inhibits the development of proliferative SPEM 
following L635 treatment. A. Immunofluorescence staining of SPEM cells with antibodies 
against GIF (red) co-labeled with GSII-lectin (green) and DAPI (blue) in mice treated with 
either control liposomes or clodronate-containing liposomes, with or without L635-treatment. B. 
Immunofluorescence staining of proliferating SPEM cells with antibodies against Ki67 (red) co-
labeled with GSII-lectin (green) and DAPI (blue). C. Quantitation of the number of GSII+ and 
GIF+ cells (SPEM) and proliferative SPEM cells. Mice treated with both clodronate and L635 
had significantly reduced SPEM cell numbers and SPEM cell proliferation (*p=0.05) compared 
to mice treated with liposomes and L635. D. qPCR showing relative expression of intestinal 
transcript markers. Clodronate treatment significantly reduced the expression of Cftr, Dmbt1 
and Gpx2 in L635-treated mice (*p=0.05). E. qPCR for IL1b, TNFa and IL10 cytokines.  
Clodronate treatment only significantly reduced IL1b expression (*p=0.05). Scale bars: 50 µm. 
 
 
DMP-777 induced SPEM does not recruit macrophages 
DMP-777 drug treatment induces SPEM over an 8-day treatment without appreciable 
inflammation (Goldenring et al., 2000a). In contrast with SPEM induced by L635 treatment, 
DMP-777-induced SPEM demonstrates only a low proliferative rate. Furthermore, DMP-777- 
Other groups have noted that clodronate treatment does not influence tissue resident 
macrophage or dendritic cell populations in some organs (Ferenbach et al., 2012; van 
Amerongen et al., 2007). Importantly, we observed a lack of immunostaining for the 
macrophage marker CD68 and only a rare Arginase II positive cell in DMP-777 treated mice, 
indicating neither M2 macrophages nor macrophages were recruited into the gastric mucosa 
during DMP-777 treatment (Figure 8D and 5E). A previous study showed local expansion of 
tissue resident macrophages in association with tissue maintenance or inflammation (Jenkins 
et al., 2011). Thus, the increase in F4/80+ cells in DMP-777 treated mice likely reflects the 
expansion of tissue resident dendritic cells within the gastric mucosa. The lack of an effect of 
macrophage depletion on SPEM development induced by DMP-777 supports the concept that 
infiltration by macrophages promotes the progression to an advanced proliferative metaplasia. 
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Figure 9: Macrophage depletion does not affect SPEM cell proliferation or F4/80 positive 
cells in DMP-777-treated mice.  Immunofluorescence of fundus in control liposome and 
liposome-DMP-777-treated mice compared to clodronate and clodronate-DMP-777-treated 
mice.  A. Immunolabeling for SPEM cells using GSII-lectin (green), gastric intrinsic factor (GIF) 
(red), and DAPI (blue).  Eight days of DMP-777 treatment induced SPEM in both liposome and 
clodronate-treated mice.  An asterisk denotes co-positive GSII and gastric intrinsic factor 
staining SPEM cells.  B. Immunolabeling to identify proliferative SPEM.  Ki67 (red) used to 
mark proliferating cells with GSII-lectin (green).  Unlike L635-treatment, DMP-777-treatment 
does not induce highly proliferative SPEM.  C.  Immunolabeling for macrophages and dendritic 
cells using F4/80 antibody (red).  D. Immunolabeling for macrophages using CD68 antibody 
(green).  DMP-777 treatment does not recruit CD68 positive macrophages to the mucosa, 
indicating that the F4/80 positive cells present are likely dendritic cells.  E. Immunolabeling for 
M2 marker, Arginase II.  There were very few M2 positive cells in DMP-777 treated mice, and 
labeling was unaffected by clodronate treatment.  F.  Quantitation of proliferative SPEM Cells 
(identified as cells triple-labeled for GSII, Ki67 and gastric intrinsic factor 20X field).  There was 
no change in the number of proliferating SPEM cells between control and macrophage-
depleted DMP-777-treated mice.  Of note, there were few proliferating SPEM cells in DMP-777 
treated mice.  G.  Quantitation of F4/80 positive cells per 20X field.  F4/80 positive cells 
significantly increased (*p=0.05) after DMP-777 treatment in all mouse models, indicating an 
expansion of dendritic cells during DMP-777 treatment that is unaffected by clodronate 
administration. Scale bars: 50 µm. 
 
 
 
 
Macrophages in L635-treated mice express M2 polarization markers 
Macrophage activation is typically described as either  “classical” (M1) or “alternative” (M2) 
(Stoger et al., 2012). M1 polarized macrophages are considered pro-inflammatory and are 
associated with iNos expression (Quiding-Jarbrink et al., 2010). In contract, M2 macrophages 
are associated with wound healing and are anti-inflammatory, but are also known to promote 
neoplasia (Murray and Wynn, 2011). We assessed the characteristics of the infiltrating 
macrophages after L635 treatment to determine M1 or M2 polarization. The F4/80+ cells at the 
base of glands after L635-treatment were identified as macrophages through co-staining with 
CD68 (Figure 9A).  The macrophages present in L635-treated mice were also positive for the 
M2 marker and hemoglobin-scavenger receptor CD163, but were negative for the M1 marker 
iNos (Figure 9B and C) (Heusinkveld and van der Burg, 2011; Verreck et al., 2006). 
Furthermore, L635-treated mice displayed a predominance of Arginase II (ArgII) positive 
macrophages, likely an M2 marker as Arginase II competes for similar substrates as iNos 
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(Figure 9D) (Bronte and Zanovello, 2005). In contrast, as noted above, F4/80+ cells in DMP-
777-treated mice were negative for macrophage markers (Figure 9) with the exception of rare 
ArgII+ cells in the submucosa (Figure 9D). 
 To further characterize macrophage polarization, M1 and M2 transcript expression was 
analyzed using RNA from fresh whole fundic tissue for qRT-PCR (Figure 10).   M1 markers 
Cxcl10, Cd3 and Nos2 were all significantly upregulated after DMP-777 and L635 
administration, but both the absolute expression levels and the magnitude of expression 
changes were small (Figure 10A). In contrast, the expression of the M2 marker Ym1 increased 
75-fold and ArgII expression increased 5-fold (Figure 10B) in L635-treated mice.  M2 
macrophages produce high levels of Ym1, which is proposed to deposit extracellular matrix for 
wound healing (Chang et al., 2001; Nair et al., 2005). Fizz1 increased to equal levels with both 
DMP-777 and L635 treatment, which may be reflective of Fizz1 expression in both 
macrophages and dendritic cells (Nair et al., 2005). Therefore, while a few iNos (protein 
expression of Nos2) positive M1 cells can be detected, the majority of macrophages infiltrating 
into the mucosa after L635-treatment were M2 polarized. 
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Figure 10: Macrophages are M2 polarized in L635-treated mice, but not in DMP-777-
treated mice. Immunofluorescence of fundic mucosa from untreated, DMP-777 and L635-
treated mice. A. Identification of macrophages by co-positive CD68 (green) and F4/80 (red) 
cells. F4/80 positive cells, negative for CD68 staining were considered dendritic cells.  F4/80 
positive cells at the base of glands in L635-treated mice were also CD68 positive. Inset in L635 
panel illustrating dual-positive F4/80 and CD68 cells. B.  Immunofluorescence staining of 
CD163 (green) marked M2 polarized macrophages.   Several CD163 positive M2 polarized 
macrophages co-labeling with F4/80 are present in L635-treated mice. Inset showing CD163 
and F4/80 co-positive cells. C. Immunofluorescence staining of the M1 marker iNos (green), 
F4/80 (red) and DAPI (blue). Inset in L635 showing rare iNos and F4/80 positive cells.  D.  
Immunofluorescence of Arginase II (green), an M2 marker, with F4/80 (red) and DAPI (blue). 
DMP-777-treated mice had a few Arginase II and F4/80 co-positive cells, mostly localized to 
the submucosa. L635-treated mice have several Arginase II and F4/80 co-positive cells within 
the mucosa.  Scale bars: 50 µm.  All insets show enlarged view of area marked by arrow. All 
co-positive cells marked by asterisk. 
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Figure 11: M2 marker transcripts are markedly increased in L635-treated mice. 
Quantitative PCR showing mRNA expression from whole fresh fundus of M1 and M2 markers 
normalized to GAPDH, shown as expression level multiplied by 1000 for scale.  A. M1 markers 
Cxcl10, Cd3, and Nos2 all significantly increase (*p=0.05) in DMP-777 and L635-treated mice.  
However, the expression levels overall of the M1 markers are very low.  B.  M2 markers 
Arginase I, Arginase II, Fizz1, and Ym1 all significantly increase in L635-treated mice (*p=0.05). 
 
 
M2 macrophages increase in human SPEM and intestinal metaplasia 
 Based on the characteristics of macrophages found in the murine model, we examined 
macrophages associated with stomach metaplasia in humans.  Normal human fundic mucosa 
contained CD68+ macrophages (Figure 11A and D).  However, in mucosa with SPEM and 
intestinal metaplasia (IM), the number of CD68+ macrophages significantly increased two to 
three-fold (Figure 11B, C and D).  Typically macrophages were dispersed throughout the 
SPEM area, while in IM the macrophages clustered together in regions around blood vessel-
like structures (Figure 11B and C inset).  Normal gastric tissue demonstrated only a few M2 
polarized macrophages labeled with CD163 (Figure 11A and E), which increased two to three-
fold SPEM and IM (Figure 11B, C and E). 
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Figure 12: M2 macrophage infiltration in human SPEM and IM. 
A. Left panel: Normal human mucosa labeled with GSII-Lectin (green) marking mucus neck 
cells and CD68 (red) for macrophages. Right panel shows CD163 (red) antibody labeling for 
M2 macrophages, GSII-Lectin (green) and DAPI (blue) in a serial section. B.  Left panel: 
SPEM in human tissue immunolabeled with GSII-Lectin (green), CD68 (red) and DAPI (blue), 
showing an increased number of CD68+ macrophages. Right panel shows an increase in 
CD163 (red) M2 marker staining cells in a serial section. Inset in right panel is showing SPEM 
surrounded by CD163+ macrophages C. Left panel: SPEM (GSII-Lectin in green) and IM show 
increased CD68+ (red) macrophages clustered around vessel-like structures.  Right panel: 
CD163 staining in a serial section demonstrates macrophages were M2 polarized in SPEM 
and IM. Inset showing M2 macrophages cluster around vessel-like structures. D. Quantitation 
of CD68+ macrophages per core in normal, SPEM and IM.  CD68 positive cells significantly 
increase (*p=0.05) from normal fundus to SPEM, and SPEM/IM.  D. Quantitation of CD163 
positive cells per core.  The number of M2 polarized macrophages significantly increased 
(*p=0.05) from normal to SPEM and SPEM/IM tissue.  Scale bars: 50 µm.  All insets show 
enlarged view of area marked by arrow. 
 
 
Discussion 
 The loss of parietal cells, also known as oxyntic atrophy, is considered an absolute 
requirement for the development of both metaplasia and intestinal-type gastric cancer (El-
Zimaity et al., 2002; Goldenring et al., 2010; Meining et al., 2001).  Nevertheless, the exact 
cause of parietal cell loss during chronic Helicobacter infection remains unclear.  Previous 
studies have investigated the role of immune factors during Helicobacter infection and their 
impact on parietal cell loss and the development of metaplasia.  Severe combined immune 
deficient (SCID) mice do not undergo parietal cell loss following H. pylori infection, implicating 
the adaptive immune system in the development of Helicobacter-associated oxyntic atrophy 
(Smythies et al., 2000). Roth et al. found that Rag1 knockout mice, deficient in mature T and B 
lymphocytes, do not lose parietal cells when infected with H. pylori (Mombaerts et al., 1992; 
Roth et al., 1999). In further studies, they found that T-cells were necessary for parietal cell 
loss during H. pylori infection (Roth et al., 1999). Therefore, the T-cell-mediated response to H. 
pylori infection results in oxyntic atrophy, a prerequisite for induction of metaplasia (Appelmelk 
et al., 1996; Roth et al., 1999). 
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 While the loss of parietal cells during Helicobacter infection requires the influence of T-
cells, the development of metaplasia appears to relate directly to parietal cell loss. Our recent 
investigations have demonstrated that SPEM is derived from transdifferentiation of chief cells 
in mice (Goldenring et al., 2010; Nam et al., 2010b; Weis et al., 2012; Yoshizawa et al., 2007). 
In the present studies, L635-treated Rag1KO mice developed proliferative SPEM and 
upregulated intestinal transcripts similar to wild type L635-treated mice.  Thus, while T-cells 
are necessary for parietal cell loss in chronic Helicobacter models to facilitate the development 
of SPEM (Roth et al., 1999), T-cells are not necessary for the development of SPEM in the 
acute L635 treatment model.  It is important to note that DMP-777 and L635 treatments directly 
induce parietal cell loss bypassing the mechanisms that require T-cell influences to induce 
oxyntic atrophy in association with Helicobacter infection. These models can be used to 
decouple the immune influences required to induce oxyntic atrophy from the mechanisms of 
chief cell transdifferentiation into metaplasia. Furthermore, studies using the drugs DMP-777 
and L635 have demonstrated that SPEM does not progress to an advanced proliferative 
metaplasia without the presence of inflammation (Goldenring et al., 2000a; Weis et al., 2012). 
Thus, the present study addresses the role of different immune factors in the development of 
advanced SPEM after parietal cell loss using the drug L635. 
 Previous studies have evaluated the role of specific cytokines secreted by T-cells such 
as IFNγ in oxyntic atrophy and SPEM (Liu et al., 2012; Tu et al., 2011). IFNγ secreted by T-
cells drives several different immune processes, including the activation of macrophages and 
upregulation of IFNγ target genes in epithelial cells (Houghton et al., 2004; Kang et al., 2005). 
Liu et al. used a knockout of Hip1r, a model of parietal cell loss through apoptosis, crossed to 
IFNγ knockout mice to show reduced metaplasia initially; but over a longer time course, loss of 
IFNγ did not impair the development of SPEM (Liu et al., 2012; Mueller et al., 2004). In 
contrast, Helicobacter-infected mice overexpressing IFNγ through the H+/K+-ATPase promoter 
develop less Helicobacter-associated gastric pathology due to increased epithelial autophagy 
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and decreased parietal cell loss, indicating that IFNγ may also have a cytoprotective role (Tu et 
al., 2011). Using a similar model to overexpress IFNγ, Syu et al. reported IFNγ induced 
metaplasia (Syu et al., 2012). In the present study, L635-treated IFNγKO mice developed 
SPEM similar to wild type mice.  The difference in our findings may depend on experimental 
conditions used to induce parietal cell loss. Furthermore, the mouse models manipulating IFNγ 
likely focus on mechanisms related to promotion of chronic parietal cell loss, whereas the L635 
treatment model causes rapid toxic loss of parietal cells.  The L635 treatment model therefore 
focuses on the regulation of the processes influencing the transdifferentiation of chief cells into 
SPEM and their development to more advanced proliferative metaplasia.  Our present data 
indicate that IFNγ is not a requisite mediator in the development of acute advanced SPEM. 
 While shorter lived than macrophages, neutrophils are a highly effective phagocytic 
cells that are tightly controlled due to their high cytotoxicity (Silva, 2010). Neutrophil-associated 
tissue damage caused by extravasation, increased vascular permeability, neutrophil-derived 
destructive enzymes and reactive oxygen species is well documented (Kozol et al., 1991; Silva, 
2010). Nevertheless, neutrophils play an essential role in clearing Helicobacter infection (Ismail 
et al., 2003). Typically, phagocytic neutrophils are scarce in the normal stomach mucosa and 
enter during infection or injury (Fox et al., 1993; Roth et al., 1999), driven in part by 
chemokines released by epithelial cells (Kozol et al., 1991) and tissue-resident macrophages 
and dendritic cells (Blaser, 1992; Evans et al., 1995; Mai et al., 1991; Wroblewski et al., 2010). 
After L635 administration, there is increased neutrophil infiltration, but neutrophil-depleted 
L635-treated mice developed similar levels of proliferative SPEM and intestinalizing transcript 
expression as in L635-treated control mice. Therefore, neutrophils are not necessary for the 
development of advanced SPEM in this model. 
 Acute injury or infection immediately stimulates antigen-presenting cells, tissue-resident 
macrophages and dendritic cells, to engulf tissue debris and foreign antigens (Silva, 2010). 
These cells secrete cytokines that not only influence the adaptive immune system through T-
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cell differentiation, but also promote the homeostasis of surrounding epithelial cells, while 
increasing the inflammatory response (Chow et al., 2011). The short time course of L635 
treatment to ablate parietal cells and induce SPEM in just three days facilitated examination of 
the influence of macrophages on SPEM induction using clodronate treatment, an experimental 
paradigm that is not practical in conjunction with chronic Helicobacter infection models. 
Clodronate-treated mice demonstrated the same number of F4/80-positive cells with or without 
L635 treatment.  The remaining F4/80-positive cells were likely tissue resident macrophages 
and dendritic cells that do not label for CD68, and are unaffected by clodronate treatment 
(Ferenbach et al., 2012). Recently, Hashimoto et al. suggested that tissue-resident 
macrophages and circulating monocytes are independently maintained at a steady state, and 
therefore tissue resident macrophages and invading monocytes have varied responses and 
may not behave similarly (Hashimoto et al., 2013). Indeed, we have observed that DMP-777 
treatment increased the number of CD68-negative, F4/80-positive cells, but clodronate had no 
effect on the induction of SPEM by DMP-777.  L635-treated macrophage-depleted mice 
demonstrated a significant reduction in SPEM cell numbers, SPEM cell proliferation and 
expression of intestinal transcripts. Therefore, while the discrete role of dendritic cells in SPEM 
induction remains unclear, the results here indicate that infiltrating macrophages contribute to 
the advanced metaplastic phenotype in L635-induced SPEM. 
 Macrophage secretion of several different pro-inflammatory cytokines is well 
documented (Beuscher et al., 1990; Mai et al., 1991). Cytokine transcript expression for IL-1β, 
which is secreted by activated macrophages, is increased significantly in L635-treated and H. 
felis-infected mice (Beuscher et al., 1990; Nam et al., 2010b). Notably, macrophage-depleted 
L635-treated mice have significantly reduced IL-1β transcript expression compared to L635-
treated control mice.  IL-1β cytokine acts to propagate the inflammatory response and inhibits 
gastric acid secretion (Beales and Calam, 1998). Transgenic mice that overexpress human IL-
1β in the stomach develop spontaneous gastritis and eventually dysplasia after a year (Tu et 
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al., 2008). However the specific role of IL-1β in the advancement of SPEM is still unknown.  
Tumor necrosis factor alpha (TNFα) and IL-10, which are secreted by activated macrophages 
and other inflammatory cell types as well as mucosal cells, increase significantly in H. felis 
mice (Beales and Calam, 1998; Nam et al., 2010b). Nevertheless, since depletion of 
macrophages did not reduce TNFα or IL-10 levels in L635-treated mice, these cytokines may 
not contribute to the progression of metaplasia in the acute SPEM model. However, it is likely 
that specific macrophage cytokines contribute to the advancement of SPEM. 
 M2 polarized macrophages are attributed to the progression of several reported disease 
states (Oshima et al., 2011a; Zaynagetdinov et al., 2011). Inhibiting macrophage infiltration 
using a monocyte chemoattractant protein-1 (MCP-1, CCL2) antagonist led to tumor 
regression in Gan mice, a murine model of gastric cancer (Oshima et al., 2011a). In GAN mice, 
infiltrating macrophages were M2 polarized, supporting our findings that M2 macrophages are 
important in the advancement of metaplasia (Oshima et al., 2011b). While we observed a 
small increase in M1 marker expression, it was minor compared to the dramatic increase 
observed in M2 marker expression. This finding, coupled with positive staining of CD163 and 
Arginase II, indicates that macrophages present in L635-treated mice are M2 polarized, but are 
not present in DMP-777-treated mice.  Therefore, while neither CD68+ macrophages nor M2 
macrophages are required for the induction of SPEM, M2 macrophages are important for 
advancing the metaplastic phenotype. This result in mice was supported in human metaplasia, 
where half of the observed macrophages where M2 polarized. Fehlings et al. reported similar 
findings of increased CD163+ cells in H. pylori-infected patients (Fehlings et al., 2012), 
supporting the concept that M2 macrophages promote SPEM progression and intestinal 
metaplasia. 
 In summary, our data suggest that circulating monocytes invade the gastric mucosa 
during L635 administration and promote the advancement of SPEM. The macrophages 
associated with advanced proliferative metaplasia were polarized towards M2, a phenotype 
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associated with promotion of tumorogenesis in mice and humans (Heusinkveld and van der 
Burg, 2011; Oshima et al., 2011b). While T-cells and neutrophils may have critical influences 
on the induction of parietal cell loss in the gastric mucosa during Helicobacter infection, these 
immune cell populations do not appear to have significant direct influences on the emergence 
of SPEM from transdifferentiation of chief cells or the advancement of SPEM to a more 
proliferative metaplasia with intestinal characteristics.  Further investigations will be required to 
define the discrete mediators released by M2 macrophages that can promote the process of 
metaplastic transition. 
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Chapter III 
IL-33 REGULATES METAPLASIA AND MACROPHAGE POLARIZATION IN THE 
STOMACH 
 
Appear as: Christine P. Petersen, Carlo DeSalvo, Eunyoung Choi, Alec Petersen, Nripesh 
Prasad, Shawn E. Levy, Theresa T. Pizarro, James R. Goldenring 
 
 
Introduction 
 Gastric cancer is a leading cause of cancer-related deaths worldwide (de Martel et al., 
2012). Intestinal-type gastric cancer, the most abundant type of gastric adenocarcinoma, is 
frequently detected at later stages due to poor early clinical indicators. Helicobacter pylori is 
the major risk factor for developing gastric adenocarcinoma by inducing chronic inflammation 
and loss of acid-secreting parietal cells (oxyntic atrophy) (Blaser and Parsonnet, 1994). Two 
different types of metaplasia are observed in the atrophic human stomach: spasmolytic 
polypeptide expressing metaplasia (SPEM) and intestinal metaplasia (Nam et al., 2010b).  
SPEM arises from the transdifferentiation of mature chief cells and is characterized by antral-
type TFF2-expressing mucus cells in the oxyntic body region of the stomach (Nam et al., 
2010b).  Increasing evidence suggests that intestinal metaplasia, characterized by Muc2-
positive goblet cells in the stomach, likely develops from SPEM lesions (Yoshizawa et al., 
2007). Both metaplasias are associated with intestinal-type cancer development in the 
stomach (Goldenring and Nam, 2010; Yoshizawa et al., 2007). However, it remains unclear 
whether SPEM or intestinal metaplasia is the precursor lineage that gives rise to gastric 
adenocarcinoma (Goldenring et al., 2010; Nam et al., 2009). Nevertheless, a chronic 
inflammatory environment promotes the development metaplasia and gastric cancer (Fox and 
Wang, 2007; Merchant, 2005). 
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 Unlike humans, mice do not typically develop goblet cell intestinal metaplasia. Instead 
SPEM progresses with increased proliferation and levels of intestinal gene expression, 
developing into intestinalized SPEM (Weis et al., 2012). Two drugs were previously utilized in 
our lab to recapitulate the process of oxyntic atrophy and study the progression of SPEM 
(Goldenring et al., 2000a; Nomura et al., 2005b). DMP-777 is a parietal cell protonophore and 
neutrophil elastase inhibitor that causes oxyntic atrophy and SPEM with minimal inflammation 
in the stomach after 10 days of treatment. L635, an analog of DMP-777, causes oxyntic 
atrophy without inhibiting the inflammatory response. Mice treated with L635 for three days 
develop a prominent inflammatory infiltrate, that promotes the progression of SPEM into a 
more proliferative metaplasia with increased expression of intestinal transcripts that resembles 
lineage changes observed after 6-12 month Helicobacter felis infection (Weis et al., 2012; 
Weis et al., 2013a).  
 Using clodronate-mediated depletion in L635-treated mice, we recently determined that 
macrophages were necessary for the development of intestinalized SPEM (Petersen et al., 
2014). Macrophage-depleted L635-treated mice had fewer proliferative SPEM cells and a 
decrease in intestinal transcripts compared to control L635-treated mice.  Therefore, 
macrophage infiltration after acute parietal cell loss drives the advancement of SPEM towards 
a more proliferative and intestinalized phenotype (Petersen et al., 2014). In addition, 
macrophages infiltrating into the mucosa after L635 treatment displayed M2-like markers 
(Petersen et al., 2014).  M2 macrophages represent the archetype anti-inflammatory, tumor-
associated macrophage driven by Th2 cytokines (Mills et al., 2000). Nevertheless, 
macrophages specialize in accordance with local environmental stimuli, and therefore are 
diverse in gene expression and function within different organ systems (Gautier et al., 2012).  
Furthermore, the generalized M1 and M2 classification that relies solely on a few markers is 
relatively simplified (Martinez and Gordon, 2014). Thus we sought to characterize 
macrophages associated with SPEM and intestinalized SPEM to determine the specialized 
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function of macrophages in the setting of acute injury and to identify factors that contribute to 
the progression of metaplasia.   
 Macrophages associated with SPEM (DMP-777-treated mice) or intestinalized SPEM 
(L635-treated mice) were isolated from the stomach corpus using fluorescent cytometric 
sorting and RNA was sequenced to generate a profile of metaplasia-associated macrophages. 
We identified IL-33 as upregulated in macrophages from L635-treated mice compared to DMP-
777-treated mice. To investigate the role of IL-33 in the induction and progression in SPEM, IL-
33 knock out mice (IL33KO) were treated with L635 and evaluated for SPEM, macrophage 
infiltration and polarization.  Overall our data suggest that IL-33 is required to induce SPEM 
following parietal cell loss and to promote Th2 cytokines, which are critical to polarize 
alternatively activated macrophages.  These findings reveal a novel inflammatory pathway in 
the stomach in response to parietal cell loss that resembles the inflammatory environment 
observed in allergy-associated airway inflammation.  
 
Methods 
Mice 
 C57BL/6J mice were purchased from Jackson Labs (Bar Harbor, ME). IL-33 knock out 
(IL33KO) mice were generated as previously described and maintained on the C57BL/6J 
background (Maywald et al., 2015).  Regular mouse chow and water ad libitum was provided 
during experiments in a temperature-controlled room with 12-hour light-dark cycles.  All 
treatment maintenance and care of animals in these studies followed protocols approved by 
the Institutional Animal Care and Use Committees of Vanderbilt University and Case Western 
Reserve University.  
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Drug Treatment 
 Three to four mice were used per group.  L635 and DMP-777 treatment and dosage 
was conducted as previously described (Petersen et al., 2014). Clodronate treatment was 
performed as previously described (Petersen et al., 2014).  
 
Macrophage Isolation and Fluorescence Activated Cell Sorting (FACS) 
 Three mice were pooled for each macrophage preparation, and three preparations were 
used for RNA sequencing. L635 and DMP-777-treated mice were sacrificed on the final day of 
treatment.  The stomach was removed and opened along the greater curvature.  Stomach 
contents were rinsed with PBS.  The antrum and forestomach were removed with a razor 
blade and discarded, and the corpus was diced into pieces roughly one mm3 in size, and 
washed with 0.07% DTT in PBS three times for five minutes.  Stomach corpus pieces were 
then enzymatically digested using 1 U/mL of Dispase in DMEM/F-12 (Stem Cell Technologies, 
Vancouver BC) for 7 min at 37°C and subsequently diluted using an equal volume of 
macrophage growth media, Iscove’s Modified Dulbecco’s Medium (ThermoFisher), with 10% 
FBS.  Pieces were sieved through a 100 µm filter (Corning) and crushed with a rubber syringe 
plunger into a single cell suspension over a 50 mL conical tube.  Cells were spun down twice 
at 500g for 10 minutes at 4°C and resuspended in PBS with 10% FBS to remove excess cell 
debris and media.  Cells were blocked using Mouse BD Fc Block (1:100, BD Pharmingen) for 
15 minutes on ice and incubated with rat anti-mouse F4/80 conjugated to PE (1:25, BD 
Bioscience) for 30 minutes on ice.  Prior to cell sorting, cells were washed twice in PBS with 
10% FBS and incubated with 4’,6-diamidino-2-phenylindol (DAPI) (1:10,000).  Cells were 
sorted using a BD FACS Aria III (BD Biosciences, San Jose, California) and initially 
segregated from debris using forward scatter (FSC) and side scatter (SSC) properties of the 
488 nm laser.  Single cells were selected using the voltage pulse geometries of the FSC diode 
and SSC photomultiplier tube (PMT) detectors. Dead cells were excluded based on their DAPI 
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staining. Macrophages expressing F4/80 were sorted directly into Trizol (Invitrogen) using a 
100 µm nozzle. RNA was extracted from Trizol and DNAse-treated (Promega) using the 
manufacturer’s protocol.  
 
Quantitative Real-time PCR analysis 
 The stomach corpus was isolated using a razor blade and placed into RNAlater or 
frozen on dry ice. Trizol was used to extract RNA from the tissue.  One µg of DNAse-treated 
(Promega) RNA was transcribed into complementary DNA using Superscript III Reverse 
Transcriptase (Invitrogen).  Quantitative real-time polymerase chain reaction was conducted 
and analyzed as previously described using SYBR Green Supermix (Petersen et al., 2014). 
The primer sequences used for Cftr, Dmbt1, Tbp, He4, Mmp12, Clu were previously reported, 
while primers for the M1 and M2 markers (Fizz1, Ym1, Arg1, Arg2, Cd3, Cxcl10, Nos2) were 
obtained from Qiagen (QuantiTect).  Results were normalized to TBP or GAPDH and 
displayed as expression level (2-ΔCt) (Petersen et al., 2014).  Statistical significance (p<0.05) 
between groups was determined with a Mann-Whitney U 1-tailed or 2-tailed test.   
 
RNA sequencing 
 Only RNA samples that had RNA integrity numbers (RIN) ≥7.0 were used. RNA was 
amplified using the NuGEN Technologies Ovation RNA-Seq System V2 kit (Part # 7102-08) 
using manufacturer's instructions.  Approximately, 2.5 µg amplified DNA from each sample 
was sheared on a Covaris S200 focused-ultrasonicator (Woburn, MA, USA) with a target yield 
of an average 200bp fragment size. The fragmented DNA was taken into standard library 
preparation protocol using NEBNext® DNA Library Prep Master Mix Set for Illumina® (New 
England BioLabs Inc., Ipswich, MA, USA) with slight modifications. Briefly, end-repair was 
done followed by polyA addition and custom adapter ligation. Post-ligated materials were 
individually barcoded with unique in-house genomics service lab (GSL) primers and amplified 
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through 8 cycles of PCR using KAPA HiFi HotStart Ready Mix (Kapa  Biosystems,  Inc.,  
Woburn,  MA,  USA).  The quantity of the libraries were assessed by Qubit® 2.0 Fluorometer, 
and the quality of the libraries was estimated by utilizing a DNA 1000 chip on an Agilent 2100 
Bioanalyzer, respectively. Accurate quantification for sequencing applications was determined 
using the qPCR-based KAPA Biosystems Library Quantification kit (Kapa Biosystems, Inc., 
Woburn, MA, USA). Each library was then diluted to a final concentration of 12.5nM and 
pooled equimolar prior to clustering. Paired End (PE) sequencing was performed on an 
Illumina HiSeq2500 following the manufacturer's protocols. Raw reads were demultiplexed 
using a bcl2fastq conversion software v1.8.3 (Illumina, Inc., San Diego, CA, USA) with default 
settings. 
 Post processing of the sequencing reads from RNA-seq experiments from each sample 
was performed as per our unique in-house pipeline. Briefly, quality control checks on raw 
sequence data from each sample were performed using FastQC (Babraham Bioinformatics, 
London, UK). Raw reads were mapped to the reference mouse genome mm9 using TopHat 
v1.4 (Langmead et al., 2009; Trapnell et al., 2009) with two mismatches allowed and other 
default parameters. The alignment metrics of the mapped reads was estimated using 
SAMtools (Li et al., 2009). Aligned reads were then imported onto the commercial data 
analysis platform, Avadis NGS (Strand Scientifics, CA, USA). After quality inspection, the 
aligned reads were filtered on the basis of read quality metrics where reads with a base quality 
score less than 30, alignment score less than 95, and mapping quality less than 40 were 
removed. Remaining reads were then filtered on the basis of their read statistics, where 
missing mates, translocated, unaligned and flipped reads were removed. The reads list was 
then filtered to remove duplicates. Samples were then grouped as treatment and control 
identifiers and quantification of transcript abundance was done on this final read list using 
Trimmed Means of M-values (TMM) (Robinson and Oshlack, 2010) as the normalization 
method. Differential expression of genes was calculated on the basis of fold change (using 
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default cut-off ≥ ±2.0) observed between defined conditions, and the p-value of the 
differentially expressed gene list was estimated by z-score calculations with Benjamini 
Hochberg False discovery rate (FDR) correction of 0.05 (Supplemental Table 1) (Benjamini, 
1995).  Differentially expressed genes underwent gene ontology (GO) analysis and pathway 
analysis using DAVID and Ingenuity Pathway Analysis tool.  
 
Immunocytochemistry 
 Mouse stomachs were fixed in 4% paraformaldehyde overnight and transferred into 
70% ethanol for paraffin embedding.  The protocol for subsequent processing and sectioning 
was previously reported (Petersen et al., 2014). Tissue sections were blocked in Protein Block 
Serum-Free (DakoCytomation) for 1 hour at room temperature. The following primary 
antibodies were incubated overnight at 4°C in Antibody Diluent with Background Reducing 
Components (DakoCytomation): goat anti-intrinsic factor (1:1000, a gift from Dr. David Alpers, 
Washington University, St. Louis, MO), rat anti-Ki67 (1:50, BioLegend clone 16A8), rabbit anti-
Ki67 (1:500, Cell Signaling), rat anti-F4/80 (1:500; Invitrogen, Grand Island, NY), goat anti-
clusterin a (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA), rat anti-Cd44v (1:25,000; 
Cosmo Bio, Japan), mouse anti-CD163 (1:200, NeoMarkers, Fremont, CA), and goat anti-IL-
33 (1:200; R&D Systems). Human metaplasia samples were obtained as previously described 
and immunolabled with mouse anti-CD68 (1:200; Abbiotec, San Diego, CA) and human 
specific goat anti-IL-33 (1:200; R&D Systems) (Leys et al., 2007). Fluorescent secondary 
antibodies (1:500) and Alexa 488 and 647-conjugated Griffonia simplicifolia lectin II (GSII-
lectin) (1:1000; Molecular Probes, Eugene, OR) were incubated at room temperature for one 
hour.  Zeiss Axio Imager M2 microscope with Axiovision digital imaging system (Zeiss, Jena 
GmBH, Germany) or an Ariol SL-200 automated slide scanner (Leica Biosystems, Buffalo 
Grove, IL) in the Vanderbilt Digital Histology Shared Resource was used to analyze sections.  
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Image Quantitation  
 Images were analyzed using CellProfiler or manually counted (Jones et al., 2008).  
Experimental groups contained three or four mice, with three to five representative images 
taken from each mouse at 20X. SPEM lineages were identified as gastric intrinsic factor and 
GSII-lectin dual positive cells.  Proliferative SPEM was identified as gastric intrinsic factor, GSII 
lectin, and Ki67 triple positive cells. A Mann Whitney U 1-tailed test was used to determine 
statistically significant differences (p<0.05). 
 
Cytokine Array 
 RNA from whole corpus was used to assess 84 genes in the Qiagen Mouse Cytokines 
and Chemokines Array (PAMM-150ZC).  RNA was transcribed into cDNA using the RT2 First 
Strand Kit (Qiagen) for the RT2 Profiler PCR Array (Qiagen) using RT SYBR Green ROX 
qPCR Mastermix (Qiagen).  An ABI StepOnePlus machine was used for the real time PCR 
experiment and data was uploaded to the Qiagen website at http://www.qiagen.com/geneglobe 
for analysis. 
 
Results 
Analysis of macrophage transcriptome from Acute SPEM models 
 We have previously determined that M2-like macrophages promote the advancement of 
SPEM (Petersen et al., 2014).  Therefore, we sought to determine the characteristics of the 
infiltrating macrophage populations in L635-treated mice that could explain the promotion of 
proliferative and intestinalizing metaplasia. F4/80 positive cells from the corpus of L635-treated 
mice and DMP-777-treated mice were isolated and RNA sequenced for transcriptome analysis 
(Figure 1).  The purity of the isolate cell populations was established by the normalized 
expression values from the RNA sequencing (Figure 2).  Macrophage-specific genes are 
enriched in both F4/80 positive cells from L635 and DMP-777-treated mice. Other immune 
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populations were assessed, such as: T-cells (Cd3e), MDSCs and neutrophils (Ly6C and Ly6G), 
mast cells (Cma1) and eosinophils (Prg2/MBP). Gastric cell lineages were also assessed for 
contamination, such as: tuft cells (Dclk1), endocrine cells (Chga), parietal cells (Chrm2, Cckbr), 
SPEM cells (Cftr, Wfdc2), and chief cells (Mib1, Mist1). After we established the RNA 
sequencing contained an enriched population of macrophages, F4/80-positive cells from the 
stomach corpus of DMP-777-treated mice were compared to L635-treated mice (Figure 3 and 
Figure 4).  Genes upregulated in macrophages associated with intestinalized SPEM from 
L635-treated mice were considered key factors of interest (Figure 3A).  Several different 
classes of genes were upregulated: macrophage-related genes (Csf1, Syk), Th2 polarizing 
cytokines (Il33, ll4), chemokines (Ccl24, Cxcl3), matrix remodeling (Mmp25, Mmp9) and 
growth factors (Hgf, Areg, VegfA) (Figure 3A).  Upregulated genes in macrophages associated 
with SPEM in DMP-777-treated mice were associated with matrix remodeling (Col14a1, 
Col6a1), macrophage-related genes (Fcer1a, H2-M2), growth factors (Fgf1, Pdgf), 
cytokines/chemokines (Tnfrsf9, Ccl12), and angiogenesis (Ephb3, Pdgfb) (Figure 4).  
 Our analysis concentrated primarily on secreted factors or receptors, as macrophages 
impact the local environment predominantly through paracrine and juxtacrine signaling (Figure 
2A) (Lu et al., 2014; Suganami et al., 2005). Another aspect assessed using the RNA 
sequencing data was differences in macrophage polarization gene markers from L635-treated 
mice versus DMP-777-treated mice (Figure 2B).   
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Figure 13. F4/80-positive cells isolated from acute SPEM models. A. Wild-type C57BL/6 
mice (n=3 per sample, 3 biological replicate samples) were treated with L635 for 3 days or 
DMP-777 for 10 days, and were sacrificed on the last day of treatment. The corpus was 
removed from the stomach and enzymatically digested into a single cell suspension.  
Macrophages were labeled using the antibody F4/80 and FACS sorted for RNA sequencing, 
n=3 replicates/each sample. B.  Immunofluorescence of representative images illustrating the 
F4/80 positive macrophages sorted from DMP-777 and L635-treated mice. Scale bars 100 mm. 
C. Representative dot plot images of the FACS sorted PE-F4/80 cell population in DMP-777 
and L635-treated mice. Macrophages sorted from DMP-777 made up 4.41% (±0.21) of cells, 
while macrophages sorted from L635-treated mice was 8.64% (±0.31).   
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Figure 14. RNA sequencing of F4/80 positive cells in L635 and DMP-777-treated mice 
show a macrophage-enriched population.  Normalized Expression values plotted (n=3) with 
SEM. Selected genes representing different cell populations are shown.  Macrophage specific 
genes, other immune cell types (T-cell receptor, neutrophils, mast cells, eosinophils), and 
gastric cell lineages (tuft cells, endocrine cells, parietal cells, SPEM cells, and chief cells). A. 
F4/80+ cells isolated from DMP-777-treated mice B. F4/80 positive cells from L635-treated 
mice.  Both data sets show enrichment in genes specific to macrophages compared to other 
cell types found in the stomach. 
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Figure 15. Transcriptome analysis of macrophages associated with SPEM and 
intestinalized SPEM. Gene expression profile of macrophages from L635-treated mice 
compared to DMP-777-treated mice; n=3 replicates/each sample. A.  Factors significantly 
upregulated (p ≥ 0.01; fold change ≥2) in macrophages from L635-treated mice.  
Representative genes selected were grouped based on function: macrophage genes, 
cytokines, chemokines, matrix remodeling, growth factors, and cell adhesion. See data also in 
Figure 3. B. Normalized gene expression of M1 and M2-associated genes in macrophages 
isolated from DMP-777 and L635-treated mice plotted with SEM. Macrophages associated 
with intestinalized SPEM (L635-treated) express increased M2-like transcripts (Alox15, Klf4, 
Il33) compared to macrophages associated with SPEM (DMP-777 treated) which have 
increased M1 genes (Il18, Sod2).  
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Figure 16. Transcriptome analysis of macrophages associated SPEM.  Gene expression 
profile of transcripts significantly upregulated (p ≥ 0.01; fold change ≥2) in macrophages 
associated with SPEM (DMP-777-treated mice), n=3 replicates/each sample.  Representative 
genes selected were grouped based on function: Matrix remodeling, macrophage related 
genes, growth factors, cytokines, and angiogenic factors.  
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 Controversy exists over M1 and M2 macrophage polarization classification, which is 
more variable than previously thought (Lawrence and Natoli, 2011; Sica and Mantovani, 2012).  
We found that macrophages from L635-treated mice and DMP-777-treated mice expressed a 
variety of M1 and M2-associated genes (Figure 3B). Specifically, macrophages from L635-
treated mice expressed higher levels of M2 genes (Klf4, Alox15, Il33, Mrc1, Ccl22), but other 
recognized M2 genes such as Fizz1, Ym1 and Arg1 were highly expressed in macrophages 
from both L635 and DMP-777-treated mice.  While macrophages from DMP-777-treated mice 
expressed higher levels of a sub-group of M1-like genes (Il18, Sod2), both L635 and DMP-777 
isolated macrophages expressed a variety of other M1 genes in similar proportion (Klf6, Irf5, 
Irf3, Tlr4).  In addition, both L635 and DMP-777 associated macrophages only expressed low 
levels of classical M1 markers (Il6, Il12, Nos2).   
 
IL-33 is necessary for SPEM induction 
 The IL-1 family member IL-33 was the most significantly upregulated cytokine in 
macrophages from L635-treated mice compared DMP-777-treated mice. To investigate the 
role of IL-33 in the initiation and progression of SPEM, we treated IL-33 knockout mice 
(IL33KO) with L635 to induce intestinalized SPEM.  Untreated IL33KO mice have a normal 
distribution and assembly of corpus cell lineages similar to wild type mice (Figure 5A). After 
L635 treatment, IL33KO mice showed parietal cell loss and inflammatory cell infiltration similar 
to control L635-treated mice (Figure 5A). To determine if IL-33 was required for macrophage 
recruitment after parietal cell loss, F4/80 positive cells were counted in L635-treated IL33KO 
mice and control L635-treated mice. Both wild-type control and IL33KO mice demonstrated 
similar numbers of infiltrating macrophages after L635 treatment (Figure 5B and 5D).  
Therefore, IL-33 loss did not affect macrophage recruitment into the stomach after acute 
parietal cell loss.  
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 Oxyntic atrophy causes chief cells located at the base of the glands to transdifferentiate 
into SPEM, as identified by GSII lectin or CD44 variant co-labeling in gastric intrinsic factor-
expressing cells (Wada et al., 2013). However, L635-treated IL33KO mice did not develop 
SPEM, visualized by the absence of metaplasia markers (GSII lectin or Cd44 variant) in gastric 
intrinsic factor positive chief cells (Figure 5C and 5E). Another indication of metaplasia 
development is the loss of Mist1, a transcription factor expressed in mature chief cells (Nozaki 
et al., 2008a). In L635-treated mice, Mist1 expression was significantly reduced; however, 
chief cells in L635-treated IL33KO mice do not lose Mist1 expression to the extent observed in 
control L635-treated mice (Figure 6A and 6B).  Therefore, chief cells in L635-treated IL33KO 
mice do not complete transdifferentiation into SPEM upon acute parietal cell loss.  
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Figure 17. IL-33 is necessary for SPEM induction. A. H&E of wild-type untreated, L635-
treated, IL33KO, and L635-treated IL33KO mice (n=3 or 4).  Untreated IL33KO mice have 
normal oxyntic gland morphology and cell lineages.  Upon L635-treatment, both wild-type and 
IL33KO have parietal cell loss accompanied by a significant inflammatory cell infiltrate at the 
base of glands.  B.  Immunofluorescence of SPEM marker GSII-lectin, macrophage marker 
F4/80 and DAPI in untreated wild-type and L635-treated control and IL33KO mice.  F4/80 
positive macrophages infiltrate into the mucosa after L635-treatment in both wild-type and 
IL33KO mice. C. Immunofluorescence of GSII-lectin, metaplasia marker Cd44v and gastric 
intrinsic factor (GIF) to visualize SPEM.   Untreated wild-type and IL33KO mice do not have 
Cd44v positive cells or double positive GSII-lectin and GIF cells at the base of the gland.  After 
L635 treatment, control mice express double positive GSII and GIF cells at the base that are 
positive for CD44v, indicative of SPEM.  L635-treated IL33KO mice do not have double 
positive GSII-lectin and GIF or Cd44v positive cells at the base of the gland.  Cd44v is positive 
in the mucus neck cell region only in L635-treated IL33KO mice.  D. Quantitation of F4/80 
positive cells in L635-treated wild-type mice and L635-treated IL33KO mice.  No significant 
change in the number of F4/80 positive macrophages.  E. The total number of chief cells (GIF 
positive only) that transdifferentiate into SPEM cells (GSII-lectin and GIF double positive) in a 
20x field for n=3 mice. IL33KO mice had a significant reduction of SPEM cell prevalence in 
response to L635 treatment, p≥0.05. Mann Whitney U 1-tailed test. Scale bars = 100 mm. 
White boxes depict the magnified insets of L635-treated control and IL33KO mice, inset scale 
bars = 20 mm. 
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Figure 18. Mist1 expression is still present in L635-treated IL33KO mice that do not 
develop SPEM. Immunofluorescence of mature chief cell transcription factor Mist1, mucus 
neck cell and SPEM marker GSII-lectin, and gastric intrinsic factor (GIF) A.  Mist1expression is 
present in the nucleus of mature chief cells (GIF positive) in wild-type untreated mice.  After 
L635 treatment, chief cells transdifferentiate into SPEM cells, marked by co-positive GIF and 
GSII-lectin.  Mist1 expression is absent in SPEM cells. B. IL33KO mice express Mist1 in chief 
cells similar to wild-type untreated mice.  After L635 treatment, IL33KO mice have fewer 
observed Mist1 positive GIF cells, however not all Mist1 is lost, indicative of the inability of 
chief cells to transdifferentiate into SPEM. Scale bars = 100 mm. 
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A hallmark of inflammation-associated oxyntic atrophy in the stomach is the development of a 
highly proliferative and intestinalized SPEM, visualized by cells triple-positive for gastric 
intrinsic factor (GIF), Ki67, and GSII-lectin.  L635-treated wild-type mice developed proliferative 
intestinalized SPEM after only 3 days of treatment (Figure 7A).  However, L635-treated 
IL33KO mice did not develop proliferative SPEM at the base of the glands (Figure 7B).  
Instead, L635-treated IL33KO mice showed Ki67-labeled mucus neck cells, indicative of 
mucus neck cell hyperplasia.  We observed an occasional Ki67 and intrinsic factor double- 
positive cell in IL33KO mice treated with L635, which was not seen in wild-type untreated or 
control L635-treated mice, and may be indicative of the inability of chief cells to 
transdifferentiate into SPEM. Furthermore, quantitative PCR confirmed the lack of SPEM (He4, 
Clu, Mmp12) or intestinalized SPEM (Cftr, Dmbt1, Etv5) associated transcripts in L635-treated 
IL33KO mice (Figure 7C and 7D). Therefore, IL-33 is necessary for the induction of SPEM 
after acute parietal cell loss.  
 
Loss of M2-polarized macrophages in L635-treated IL33KO mice 
 Our previous study determined that M2-like macrophages were key in developing 
intestinalized SPEM (Petersen et al., 2014). Since IL-33 does not prevent macrophage 
infiltration into the mucosa after L635-treatment (Figure 5D), we sought to determine if 
macrophage polarization was altered upon the loss of IL-33 using the M2 marker CD163.  We 
observed that L635-treated IL33KO mice had a loss of CD163-positive macrophages within the 
mucosa compared to L635-treated control mice (Figure 8A).  To identify if macrophages were 
polarizing towards M1, we immunolabeled with iNos and found an increase in iNos positive 
macrophages in IL33KO-L635-treated mice compared to L635-treated wild-type mice (Figure 
8B). Quantitative PCR on RNA from whole corpus tissue revealed a significant decrease in 
only one M2 marker, Ym1, and confirmed upregulated M1 markers (Cd3 and Cxcl10) (Figure 
8C and 8D). Ym1 and CD163 are both highly expressed in M2a macrophages specifically, 
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which may indicate that IL-33 may be important in inducing M2a macrophage polarization in 
the stomach. 
 
 
Figure 19. IL33KO mice treated with L635 do not develop proliferative or intestinalized 
SPEM after acute parietal cell loss.  A.  Immunofluorescence staining of GSII-lectin, Ki67 
and GIF to identify proliferative SPEM.  L635-treated wild-type mice develop proliferative 
SPEM at the base of the gland (triple positive for Ki67, GSII-lectin, GIF).  L635-treated IL33KO 
have increased Ki67 positive GSII-lectin cells in the mucus neck cell region, but do not have 
proliferative SPEM cells at the base of the glands.  Scale bars = 100 mm. White boxes are 
magnified in the insets, inset scale bars = 10mm. B. Quantitation of Ki67 positive SPEM cells.  
The percent of proliferating SPEM cells per 20x, n=3 mice. IL33KO mice treated with L635 
have a significant reduction in proliferative SPEM present compared to L635-treated wild-type 
mice, p≥0.05.  C. Quantitative RT-PCR of SPEM markers from whole corpus RNA. Increased 
SPEM markers (He4, Clu, Mmp12) are detected in wild-type mice after L635 treatment. 
IL33KO mice treated with L635 have significantly decreased SPEM transcripts compared to 
wild-type L635-treated mice, that do not significantly change compared to untreated IL33KO 
mice, p≥0.05. D. Quantitative RT-PCR of intestinalized SPEM markers from whole corpus RNA. 
Wild-type mice have increased intestinal transcripts (Cftr, Dmbt1, Etv5) after L635 treatment, 
p≥0.05.  L635-treated IL33KO mice have significantly reduced Cftr and Dmbt1 message 
compared to wild-type L635-treated mice, p≥0.05. 
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Figure 20. IL33 is required for macrophage M2 polarization after acute parietal cell loss.  
A. Immunofluorescence of M2 marker CD163, macrophage marker F4/80 and DAPI. F4/80 
positive macrophages infiltrate into the mucosa after L635 treatment and are co-positive for 
CD163.  L635-treated IL33KO mice have increased F4/80 positive macrophages after acute 
parietal cell loss, but are not positive for the M2 marker CD163.  B. Immunofluorescence of M1 
marker iNos, GSII-lectin and DAPI.  L635-treated mice have very few iNos positive 
macrophages. Increased M1 macrophages are observed in L635-treated IL33KO mice.  Scale 
bars are 100 mm. Insets are magnified regions, scale bars 10mm. C. Quantitative RT-PCR of 
M1 markers (Cxcl10, Cd3 and Nos2) from whole corpus RNA.  L635-treated IL33KO mice 
have a significant increase in Cxcl10 and Ccl3 message compared wild-type L635-treated 
mice, p≥0.05.  D. Quantitative RT-PCR of M2 markers.  Only Ym1 was significantly reduced in 
L635-treated IL33KO mice compared to wild-type L635-treated mice, p≥0.05. No significant 
change detected in Arg1, Arg2 or Fizz1. 
  
 We used a mouse specific cytokine and chemokine array to determine if M2a 
macrophage polarization or other cytokines/chemokines were altered in L635-treated IL33KO 
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mice.  Two different categories of genes were down-regulated in L635-treated IL33KO mice 
compared to L635-treated wild-type mice: M2a macrophage-associated chemokines and Th2- 
related cytokines (Figure 9A and 9B). The alternatively activated macrophage M2a cytokine 
signature reflects high expression of Ccl11, Ccl17 and Ccl24, which were significantly 
decreased in L635-treated IL33KO mice compared to L635-treated wild-type mice (Figure 9A). 
Furthermore, Th2-related cytokines (IL4, IL5, IL9, IL13) were significantly decreased in L635-
treated IL33KO mice (Figure 9B). Of note, IL-33 and Th2 cytokines were not necessary for 
macrophage recruitment upon acute parietal cell loss or for the regulation of other M2 genes 
(Arg2, Arg1, Fizz1) in infiltrating macrophages after parietal cell loss (Figure 4D and 3D).  
 
 
 
Figure 21.  IL33 is required for M2a macrophage polarization and the production of Th2 
cytokines. Mouse chemokine and cytokine array (Qiagen) for 84 different target genes on 
whole stomach corpus RNA from L635-treated mice and L635-treated IL33KO mice (n=3). 
Seven genes were significantly (p≥0.05) decreased L635-treated IL33KO mice compared to 
control L635-treated mice. Genes were grouped based on function. A. Alternatively activated 
macrophage-related chemokines (Ccl11, Ccl24 and Ccl17) and were all significantly 
decreased in L635-treated IL33KO mice. B. Th2-related M2 macrophage polarizing cytokines 
were significantly decreased in L635-treated IL33KO mice compared to L635-treated mice.   
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IL-33 positive macrophages in human SPEM and Intestinal Metaplasia  
 We investigated whether IL-33 was expressed in macrophages associated with SPEM 
and intestinal metaplasia in arrayed samples from human corpus (Leys et al., 2007). Our 
previous study determined that the majority of macrophages in metaplasia were M2 polarized 
(Petersen et al., 2014). We immunolabled for CD68 and IL-33 and determined that all 
macrophages associated with both SPEM and intestinal metaplasia in humans were IL-33 
positive (Figure 10A and 10B).  Therefore, IL-33 may have a role in metaplasia development, 
intestinalization and macrophage polarization in neoplastic progression within the human 
stomach. 
 
 
 
 
Figure 22.  Macrophages associated with Human SPEM and Intestinal metaplasia are IL-
33 positive.  Immunofluorescence of macrophage marker CD68, IL-33, and SPEM marker 
GSII-lectin in human SPEM and Intestinal Metaplasia biopsy samples.  A. Human SPEM has 
IL-33 positive macrophage infiltrating into the mucosa.  B. Intestinal Metaplasia has CD68 
positive macrophages that are co-positive for IL-33.  Scale bars are 100 mm, inset scale bar is 
20 mm.  Asterisks in intestinal metaplasia denote similar area in the inset. 
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Discussion 
 In the current study, we establish that IL-33 is required for the development of 
metaplasia in the corpus of the stomach. IL-33 was necessary for the polarization of infiltrating 
macrophages towards M2 after acute parietal cell loss. In the absence of IL-33, chief cells 
were unable to transdifferentiate into SPEM, even in the presence of a substantial macrophage 
infiltration following L635 treatment.  Our previous study showed that infiltrating M2 polarized 
macrophages were necessary for the intestinalization of metaplasia (Petersen et al., 2014).  
Here we found that IL-33 is required for the polarization of infiltrating macrophages towards 
M2a and the induction of SPEM. Investigations using our acute SPEM models provide an in 
vivo method to study the effects of inflammation on the metaplastic process, recapitulating the 
process observed in Helicobacter infection (Weis et al., 2012). The data presented here 
support a novel pathway for metaplasia induction, where IL-33 is a critical component in 
initiating metaplasia development and regulating the polarization of infiltrating macrophages 
towards M2a that subsequently drive the intestinalization of metaplasia in the stomach. 
 Our acute metaplasia model drug systems in the stomach are unique in respect to the 
ability to separate discrete inflammatory mechanisms in the progression of SPEM (Weis et al., 
2012). Mice treated with DMP-777 develop SPEM after 10 days, whereas SPEM induced in 
L635-treated mice progresses in the setting of acute inflammation into a highly proliferative 
and intestinalized SPEM lineage in three days (Nam et al., 2010b). We identified differentially 
regulated genes that could promote the advancement of metaplasia by characterizing 
macrophages associated with SPEM (DMP-777-treated mice) and intestinalized SPEM (L635-
treated mice). Both populations of macrophages in DMP-777 and L635-treated mice had 
similar expression patterns of M1 and M2 markers. However, markers typically used to classify 
the macrophage subclasses were not adequate to distinguish between the functionally distinct 
macrophage populations associated with SPEM versus intestinalized SPEM.  Additionally, 
macrophage transcriptomes in the stomach after acute parietal cell loss revealed a general 
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profile indicative of mucosal injury repair, including genes involved with matrix remodeling, 
angiogenesis, chemokines/cytokines, and growth factors.  
 Previous studies have demonstrated the effect of specific cytokines on evoking 
inflammation to induce metaplasia in the stomach. Recombinant human IL-1b or IFNg 
expressed by parietal cells in transgenic mice is sufficient to induce gastric inflammation and 
dysplasia within the stomach (Syu et al., 2012; Tu et al., 2008). Administration of IL-11 also 
induces inflammation and metaplasia in the stomach (Howlett et al., 2012). Likewise the 
inhibition or ablation of different cytokines/chemokines can prevent macrophage infiltration and 
impact metaplasia.  Ccl2 inhibition prevents macrophage infiltration and causes tumor 
regression in SPF-Gan mice (Oshima et al., 2011a). Il1b null mice infected with Helicobacter 
pylori have decreased macrophage and neutrophil recruitment into the mucosa that 
corresponded with reduced gastric pathology (Shigematsu et al., 2013). Therefore, stomach 
metaplasia progression or reversal directly relates to macrophage infiltration within the gastric 
mucosa. The work presented here identifies IL-33 as a key cytokine required to induce 
metaplasia separate from the induction of macrophage infiltration.  
 IL-33 was first reported in 2005 as the ligand to the orphan IL-1 receptor ST2 (Schmitz 
et al., 2005). IL-33 localizes to endothelial cells, epithelial cells, dendritic cells and activated 
macrophages in mice, and only activated dendritic cells and macrophages in humans 
(Kurowska-Stolarska et al., 2008; Schmitz et al., 2005). Administration of IL-33 is sufficient to 
induce hypertrophy and mucus metaplasia in the airway, stomach, and intestine, which is 
accompanied by an infiltration of myeloid cells and eosinophils (Buzzelli, 2015; Kurowska-
Stolarska et al., 2008; Prefontaine et al., 2010; Schmitz et al., 2005; Stolarski et al., 2010). In 
this study, we investigated the requirement of IL-33 in the development and progression of 
metaplasia after finding it was upregulated over 6-fold in macrophages isolated from L635-
treated mice compared to DMP-777-treated mice. IL-33 knockout mice treated with L635 
showed parietal cell loss, nevertheless chief cells failed to transdifferentiate into SPEM or 
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progress to intestinalized SPEM. While loss of IL-33 did not impact the recruitment of 
macrophage infiltrates in the gastric mucosa after parietal cell loss, infiltrating macrophages 
were not M2 polarized. Thus indicating that IL-33 is critical for M2 polarization of recruited 
macrophages in the stomach.  
 Previous studies have focused on the role of IL-33 and inflammation in the context of 
allergic inflammation. In the airway, IL-33 upregulation promotes Th2 cytokine production by T 
helper cells, macrophages, and group 2 innate lymphoid cells (ILC2s) (Blom et al., 2011; 
Cayrol and Girard, 2014; Kurowska-Stolarska et al., 2009; Schmitz et al., 2005; Smith et al., 
2015). The rapid release of IL-4 and IL-13 increase the M2a macrophage genes, CCL17 and 
CCL24 (Kurowska-Stolarska et al., 2009). In addition, Th2 cytokines IL-4, IL-9 and IL-13 can 
induce mucus production in the airway in response to allergen challenge (Dabbagh et al., 
1999; Kurowska-Stolarska et al., 2008). We observed a similar phenotypic response after 
acute parietal cell loss and hypothesized that cytokines/chemokines downstream of IL-33 
could impact the induction or progression of metaplasia. We found that IL33KO mice treated 
with L635 had decreased Th2 cytokines (IL4, IL5, IL9, IL13) and M2a-associated cytokines 
(CCL17, CCL22, CCL24) when compared to controls.  Therefore IL-33 in the stomach is 
required to promote the expression of IL-4 and IL-13.  The upregulation of IL-4, IL-9 and/or IL-
13 is known to mucus production, which is a hallmark of chief cells transdifferentiating into a 
metaplastic mucus cell lineage (SPEM). Our previous study determined that M2 macrophages 
were necessary for the intestinalization of SPEM, but did not clarify the M2 subclass  (M2a, 
M2b or M2c) (Petersen et al., 2014),(Mantovani et al., 2004). Data presented here suggests 
that recruited macrophages polarize towards M2a after L635 treatment and that IL-33 
necessary for macrophage polarization. Thus, we suggest that IL-33 is simultaneously driving 
metaplastic transition through downstream targets to upregulate mucus secretion in chief cells 
while potentiating the intestinalization of SPEM by polarizing recruited macrophages towards 
M2a.  Another similarity between mucus metaplasia development in the airway and stomach is 
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the upregulation of TFF2 (Nikolaidis et al., 2003). IL-33 promotes TFF2 expression in asthma, 
and TFF2 expression is upregulated in chief cells transdifferentiating into SPEM after parietal 
cell loss (Schmidt et al., 1999a; Wills-Karp et al., 2012). This further suggests that key 
functions of inflammation in the airway (airway hyperactivity or allergic inflammation) parallel 
similar processes observed in SPEM regarding macrophage polarization and expansion of 
mucus-producing cell lineages.  Allergic inflammation in the airway relies on the Th2 cytokines 
IL-4 and IL-13 through IL-33 to promote mucus cell metaplasia development and drive M2a 
polarization (Kurowska-Stolarska et al., 2008). We describe a similar process in the stomach, 
where IL-33 is necessary for metaplasia induction and intestinalization of SPEM. Future 
studies will be needed to understand further the roles of IL-13 and IL-4 in the induction and 
progression of metaplasia and macrophage function after acute parietal cell loss.  
 In summary, our investigation of the transcriptional profile of macrophages associated 
with intestinalized SPEM in L635-treated mice revealed the requirement of IL-33 in the 
development of SPEM.  We further demonstrated that IL-33 is necessary to promote a Th2 
inflammatory response and M2a polarization of recruited macrophages, which drives 
initialization of SPEM. The identification of IL-33 as a critical regulator of macrophage 
polarization and Th2 cytokine production suggests a central role for immune cell regulation of 
the epithelial response to acute injury.   These observations provide a novel pathway and 
model for understanding the inflammatory response in the stomach after parietal cell loss.  
Furthermore, conclusions presented here suggest that therapeutic modalities currently used to 
treat inflammation in the airway could potentially modulate the inflammatory response in the 
stomach to prevent metaplasia progression towards gastric adenocarcinoma. 
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Chapter IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
1. Conclusions 
Inflammation is a key step in the development and progression of metaplasia in the 
stomach.  In humans, Helicobacter infection occurs over years to incite oxyntic atrophy and 
chronic inflammation that predispose individuals to develop gastric cancer. Murine models of 
metaplasia have provided insights into the origin of metaplasia and cellular processes that 
progress metaplasia.  To summarize, studies using immunodeficient murine models 
established that CD4+ T cells are necessary for Helicobacter-associated oxyntic atrophy 
(Eaton et al., 2001; Roth et al., 1999). After parietal cell loss, metaplasia develops from 
transdifferentiation of chief cells into spasmolytic polypeptide expression metaplasia (SPEM).  
SPEM can further progress to intestinalized metaplasia (intestinal metaplasia (IM) in humans, 
intestinalized SPEM in mice) in the presence of inflammation (Nam et al., 2010b; Yoshizawa et 
al., 2007). Whether SPEM or IM is the origin for gastric adenocarcinoma is still unknown.  
However, SPEM does not progress towards a more advanced intestinalized phenotype in mice 
without the influence of an inflammatory component (Weis et al., 2013a).  The work presented 
here details the inflammatory mediators necessary for the induction and progression of SPEM, 
which could provide potential therapeutic targets. 
Previous studies in our lab identified that while mice do not develop intestinal metaplasia, 
SPEM progresses to become more intestinalized over time.  This progression is directly 
associated with the inflammatory response, as SPEM in L635-treated mice and Helicobacter 
felis infected mice has an increase in intestinal-associated transcripts (CFTR, DMBT1, ETV5 
and GPX2) while non-inflammatory DMP-777-treated mice do not (Weis et al., 2013a).  The 
first study, detailed in Chapter 2, sought to determine the inflammatory cells necessary for the 
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intestinalization and advancement of SPEM (Petersen et al., 2014).  T cells, B cells, IFN 
gamma, neutrophils and macrophages are all associated with Helicobacter infection and were 
therefore were identified as potential targets that could contribute towards the progression of 
metaplasia. Therefore IFN gamma knock out mice, Rag1 knock out mice (lack T and B cells), 
neutrophil-depleted mice, and macrophage-depleted mice were all treated with L635 to 
determine if any of these cell types could solely prevent the progression of metaplasia. The 
results of this study revealed that only macrophages were necessary for the progression to 
intestinalized SPEM. Macrophage-depleted mice treated with L635 had decreased 
intestinalized transcripts, SPEM cells, and proliferation compared to control L635-treated mice. 
Further characterization of gastric macrophages present in L635-treated mice revealed a 
predominant M2 polarization (CD163, Ym1, Arg1, Arg2 positive), whereas macrophages in 
DMP-777-treated mice were not positive for M2 markers.  Typically, M2-macrophages are 
associated with tumors and an anti-inflammatory response that is promoted by Th2 cytokines 
(Mills et al., 2000). M2 polarized macrophages are also implicated in driving the development 
of pancreatic acinar to ductal cell metaplasia (ADM), the neoplastic disease state prior to 
pancreatic ductal adenocarcinoma (PDAC) (Liou et al., 2013). Therefore the association of M2 
macrophages in metaplastic tissues appears to promote cancer development. Nevertheless, 
the mechanism by which macrophages are promoting disease advancement is not well 
understood.  
 Our next aim was to further identify potential macrophage produced targets that could 
promote intestinalization of SPEM. Recent studies have identified diversity within macrophage 
populations according to the environmental niche (Davies et al., 2013; Martinez and Gordon, 
2014). Therefore, our goal was not only to identify target genes, but also to characterize further 
gastric macrophages. Macrophages from the corpus of DMP-777 and L635-treated mice were 
isolated and RNA sequenced to compare SPEM-associated macrophages (DMP-777-treated 
mice) and intestinalized SPEM-associated macrophages (L635-treated mice). Isolating 
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macrophages from untreated wild-type mice was repeatedly unsuccessful. This is in part due 
to the low prevalence of tissue-resident macrophages in the stomach.  Nevertheless, even with 
multiple mouse stomachs pooled together, RNA obtained from wild type macrophages had 
inadequate quality for RNA sequencing. One possibility is that macrophages associated with 
SPEM may be easier to remove from the epithelium because the mucosa in DMP-777-treated 
mice and L635-treated mice is damaged. The damaged mucosa may assist in tissue 
dissociation and therefore ease in the removal of macrophages. Macrophages within an 
undamaged wild-type stomach may be too well associated with epithelial cells to be removed 
without significant damage or death to the population. We therefore progressed with 
macrophage RNA from SPEM and intestinalized SPEM to be analyzed by HudsonAlpha 
(Huntsville, AL) and generated a list differentially expressed genes. Exactly 1641 genes were 
found to be significantly different (≥ 2 fold difference and p≥0.01) between the two groups.  Of 
this, 811 genes were identified as being upregulated in macrophages isolated from DMP-777-
treated mice, and 830 upregulated in L635-treated mouse macrophages. To determine 
potential targets, genes were classified into groups (cytokines, chemokines, matrix remodeling, 
angiogenic factors, cell adhesion) and genes with the greatest fold changes were examined 
first. The IL-1 family member IL-33 was the most significantly upregulated cytokine/chemokine 
in macrophages isolated from L635-treated mice compared to DMP-777-treated mice (6-fold 
increase).  Using IL-33 knockout mice (IL33KO), we sought to identify whether IL-33 played a 
role in the development or progression of SPEM.  IL33KO mice were treated with L635 and 
had typical parietal cell loss with had normal numbers macrophages recruited into the mucosa. 
This is of particular importance as our previous data shows macrophage depletion (or failure to 
recruit) would prevent the progression of SPEM.  Thus the fact that IL-33 did not impact 
macrophage recruitment is critical to the study. Unexpectedly we found that L635-treated 
IL33KO mice did not develop SPEM or intestinalized SPEM in response to parietal cell loss. 
We anticipated that SPEM may not become intestinalized, and instead SPEM development 
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was prevented altogether. To determine how IL-33 could be impacting SPEM induction, we 
decided to do a cytokine array to see what other factors could potentially be differentially 
expressed. IL-4, IL-5, IL-9 and IL-13 (Th2 cytokines) were all found to be significantly reduced 
in L635-treated IL33KO mice compared to control L635-treated mice.  The reduction of IL-4 
and IL-13 are of particular interest as both have been shown to induce mucus metaplasia in 
the airway and intestine.  Specifically IL-13 is required for the development of mucus 
metaplasia in those tissues. Thus, IL-33 in the stomach appears to induce IL-13 expression 
that could stimulate chief cells to transdifferentiate to SPEM cells and produce mucus. Further 
insight into this topic is discussed in future directions. Among other cytokines also decreased 
in L635-treated IL33KO mice were CCL11, CCL17 and CCL24, which are a signature of M2a 
polarized macrophages. Other M1 and M2 cytokines were assessed and we determined that 
the recruited macrophages in L635-treated IL33KO mice did not polarize towards M2a. Taken 
together, these data show that IL-33 is necessary for M2a macrophage polarization, Th2 
cytokine induction in the stomach, and transdifferentiation of chief cells into SPEM cells. While 
previous studies show that exogenous administration of IL-33 is able to induce mucus 
metaplasia in the airway, stomach and intestine, (Buzzelli, 2015; Kurowska-Stolarska et al., 
2009; Prefontaine et al., 2010) our data suggest that IL-33 is required for metaplasia 
development and macrophage polarization to induce intestinalization. In summary, our studies 
investigating the role of the immune system in the development and progression of SPEM 
identified M2 macrophages and IL-33 as key regulators for M2a macrophage polarization and 
chief cell transdifferentiation into SPEM.  These findings parallel key inflammatory responses 
observed in allergic inflammation and airway hyperactivity.  Thus a unified paradigm has 
developed illustrating that the inflammatory response to injury in the airway and stomach 
promote a similar processes of inducing Th2-driven mucus metaplasia that is associated with 
M2a polarized macrophages. 
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2. Future Directions 
The studies detailed here identify specific aspects of the immune system that directly 
regulate metaplasia development and progression in the murine stomach.  Further studies 
should focus on investigating the mechanisms by which these immune components influence 
the induction of metaplasia and the progression of metaplastic lesions.  Specifically, there are 
three different categories that contain follow-up questions: IL-33-related studies, Th2 cytokines 
in the induction and intestinalization in SPEM, and other immune targets to explore. 
 
IL-33-related studies. 
Chapter 3 details the identification of IL-33 as a critical factor for macrophage polarization 
and SPEM induction.  The resulting questions pertain to how IL-33 induces these responses.  
Buzzelli et al. described that IL-33 acted as stomach alarmin by exogenously administering 
recombinant IL-33 into mice, resulting in SPEM accompanied by an inflammatory response 
(Buzzelli, 2015). Scientists typically use two definitions to designate a specific 
cytokine/chemokine as an alarmin (Haraldsen et al., 2009).  First, is the ability to alert other 
cell types to damage (i.e. a danger signal), which is synonymous to the definition of DAMP 
(damage-associated molecular pattern) (Foell et al., 2007). Therefore a second more specific 
definition was imposed to only include factors released by damaged/injured/infected cells that 
attract the immune system in effort to amount an inflammatory response (Oppenheim et al., 
2007; Oppenheim and Yang, 2005). For example, HMGB1 is a protein located in the nucleus 
that aids in the binding of transcription factors to DNA, and when released from apoptotic or 
necrotic cells causes a strong inflammatory response (Scaffidi et al., 2002). IL-33 is normally 
expressed in the nucleus of surface epithelial cells in the corpus and recruited macrophages 
after parietal cell loss (Schmitz et al., 2005). Nevertheless, neither macrophages nor the 
surface epithelial cells undergo apoptosis or necrosis during Helicobacter infection or acute 
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parietal cell loss using the drugs L635 or DMP-777. Thus, while exogenously administered IL-
33 does act as an alarmin in the stomach by recruiting inflammatory cells, it is unlikely that 
endogenous IL-33 functions through this mechanism. Instead is it plausible that IL-33 is acting 
as a transcription factor to affect downstream signaling instead of acting as an alarmin.  The 
role of IL-33 in the nucleus is still not well described; however, IL-33 is thought to effect 
transcription by associating with heterochromatin (Carriere et al., 2007). Ali et al were the first 
to describe that nuclear IL-33 is able to repress NF-kB signaling by associating with p65 (Ali et 
al., 2011). Therefore, accessing the downstream factors mediated by IL-33 in the inflamed 
stomach in both surface epithelial cells and infiltrating macrophages through a method such as 
ChIP-sequencing would identify novel IL-33 target genes. Determining how IL-33 is being 
differentially regulated depending on the source cell would also determine how epithelial cell 
associated IL-33 differs in gene transcription regulation compared to IL-33 associated with 
macrophages. A similar follow up question is how IL-33 from different cell sources impacts the 
overall metaplastic phenotype. A potential approach would be a bone marrow transplantation 
experiment, where IL33 knock out mouse bone marrow would be transplanted into a wild-type 
C57Bl/6 mouse (WTIL33koBM) and IL-33 knock out mouse would receive wild-type bone marrow 
(IL33KOwtBM). Acute parietal cell loss could be induced using L635 in both models and the 
phenotype accessed to determine how the source of IL-33 in the stomach effects metaplasia 
development. It could be that IL-33 solely from macrophages is important in both inducing the 
production of IL-13 from ILC2 cells to promote mucus production and macrophage polarization. 
Finally, to ensure that IL-33 is important in a more natural setting of metaplasia development, 
IL-33 knock out mice should be infected with Helicobacter felis. 
 
Th2 cytokines in the induction and intestinalization in SPEM. 
The aim of the study detailed in Chapter 3 was to determine how infiltrating M2 
macrophages were intestinalizing metaplasia. We identified IL-33 as a factor important in both 
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metaplasia induction and macrophage polarization.  Further studies are needed to separate 
the two effects to better understand how IL-33 is preventing chief cells from transdifferentiating 
into SPEM cells and how the lack of M2 polarized macrophages affects SPEM development 
and progression.  To approach these two questions, a few different methods could be 
employed. First, one potential explanation for the changes observed is the significant reduction 
of Th2 cytokines in the stomach of IL33KO mice treated with L635 compared to control L635-
treated mice.  Exogenous treatment of Th2 cytokines IL-4, IL-13 and IL-9 are able to induce 
mucus metaplasia in the airway in mice through IL-33 (Dabbagh et al., 1999; Kurowska-
Stolarska et al., 2008). Therefore understanding how the loss of different Th2 cytokines 
impacts the development of SPEM is an imperative question. It is a viable hypothesis that if 
Th2 cytokines can induce mucus metaplasia, perhaps in their absence metaplasia 
development is prevented. An approach would be to use genetic knock out mouse models for 
the ligands and receptors (all mice are viable and available) and treat each with L635.  The 
cytokine IL-13 is of specific interest, as other studies detailed that manipulations within IL-13 
signaling through deletion of the IL-13 receptor, IL4ra, or of IL-13 itself abrogates mucus 
production in the intestine (von Moltke et al., 2015).  While IL-4 is important for immune cell 
recruitment, IL-4 is not required for mucus production in the airway or intestine (Cohn et al., 
1997).  Another approach could be administering exogenous Th2 cytokines to L635-treated IL-
33 knock out mice to see which parts of the phenotype are ameliorated. On a similar note, 
DMP-777 treated mice could be administered different cytokine cocktails (IL-33, IL-4, IL-13, IL-
9) to push an intestinalized SPEM phenotype or macrophage polarization. After each cytokine 
administration, mice should be checked for SPEM intestinalization and macrophage 
polarization to determine the effect of cytokines on the metaplastic progression and immune 
infiltrate. 
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IL-25 and innate lymphoid cells (ILCs). 
In effort to expand the immunological studies of SPEM progression in the stomach, new 
cytokines and immune populations should be explored that have yet to be evaluated. 
Specifically, the cytokine IL-25 and the innate lymphoid cell population (ILCs) could be of 
importance in Th2 cytokine regulation and expansion of different cell types during inflammation.  
The IL-17 family member IL-25 is of specific interest due to its role in allergic inflammation and 
promoting a Th2 cytokine response (Hongjia et al., 2014).  Data presented in Chapter 3 
indicate that the inflammatory response to acute parietal cell loss in the stomach parallels the 
Th2 cytokine and M2a signature observed in allergic airway inflammation (Kurowska-Stolarska 
et al., 2009). Mice infused with IL-25 have induced expression of IL-4, IL-5 and IL-13, causing 
eosinophilia and pathological changes in the GI tract.  Specifically, IL-25 administration caused 
stomach changes in the corpus described as “a vacuolation of stomach mucus cells” that 
appear to be similar to the appearance of SPEM cells (Fort et al., 2001).  IL-25 is also 
expressed in the stomach under normal conditions in DLCK1-positive tuft cells that expand in 
response to parietal cell loss (Saqui-Salces et al., 2011; von Moltke et al., 2015). Thus, 
perhaps tuft cell expansion during atrophic gastritis may be in part to increased IL-25 
production.  IL-25 functions to activate and expand tissue resident ILC2 cells that are a 
significant producer of type 2 cytokines (IL-4, IL-13) (Licona-Limon et al., 2013).  In the 
absence of IL-25, IL-33 also activates ILC2 cells to produce type 2 cytokines that evoke mucus 
metaplasia.  However, the converse is not true, IL-25 cannot replace the function of IL-33. 
Nevertheless, the key downstream regulator is IL-13, where in the absence of IL-13 neither IL-
25 nor IL-33 are unable to induce mucus metaplasia in the airway or intestine.  Thus further 
adding evidence to the IL-13 null mouse or administrations of IL-13 to IL-33 knock out mice in 
the experiments detailed above. IL-25 expression should be studied in our acute parietal cell 
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loss models (L635 and DMP-777) along with chronic infection with Helicobacter felis at 
different time points in context with tuft cell expansion and function. 
 In conclusion, it appears that in response to acute parietal cell loss there are several 
immuno-epithelia circuits synergizing to promote SPEM. While the timing of these processes is 
unclear, parietal cell loss induces the expansion of tuft cells (increased IL-25) and surface 
epithelial cells (increased IL-33). These two cytokines working through IL-9 would most likely 
function to activate the tissue resident ILC2 populations that in turn produce IL-13 (among 
other Th2/type 2 cytokines). IL-13 may then induce chief cells to transdifferentiate into SPEM 
cells through an unknown mechanism. Simultaneously, macrophages infiltrating into the 
mucosa in response to parietal cell loss are polarizing towards M2a in the Th2 cytokine 
environment.  M2a polarized macrophages expressing IL-33 are then able to promote the 
intestinalization of SPEM that progresses metaplasia towards adenocarcinoma. 
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